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Abstract
Tau fibrils are a pathological hallmark of over 20 neurodegenerative
disorders, including Alzheimer’s disease. There currently is no cure for these
diseases and treatments are limited. Once Tau fibrils form in the brain, they
propagate down neuronal networks, and this spreading is linked to disease
progression. Studying the behavior and structure of Tau monomer and Tau
aggregates therefore may give insight into methods by which the spread of Tau
fibrils can be inhibited. The structures of the Tau fibrils from different diseases
are thought to vary, partially giving rise to the different disease phenotypes. Tau
natively binds to microtubules by either three or four imperfect repeat regions,
giving rise to the naming convention of 3R and 4R Tau. In solution, full-length
Tau exists as a disordered monomer in dynamic conformational equilibrium. This
solution-phase heterogeneity could, in part, explain conformational diversity of
Tau fibrils.
A homogeneous set of Tau fibrils transitioned to a new heterogeneous
population of conformers after multiple cycles of seeding. The original fibrils were
formed under stirring conditions, which enhanced the fragile population. Under
the quiescent growth conditions of multiple cycles of seeding, the faster growing
populations became the dominant set of conformers. This explains how a new
ii

dominant fibril population can evolve from minor subpopulations. These findings
demonstrate that changes in the selective pressures on Tau fibrils during fibril
propagation could lead to the formation of polymorphs with differing clinical
consequences.
Microtubule associated protein 2 (MAP2) is a neuronal homologue to Tau
and performs similar functions in the cell. MAP2 has not been shown to be a
major antigenic component of the neurofibrillary tangles associated with disease.
However, this does not exclude their presence in small quantities. Microtubule
binding repeat regions from 3R and 4R MAP2 slow nucleation and block seeded
aggregation of 4R Tau protein. Also, as few as a single MAP2 molecule bind to
and cap the 4R Tau fibril end. This could account for the inhibition via disruption
of the ability of Tau to subsequently bind to the capped fibril end. MAP2 inhibition
of Tau fibril formation and progression could be a natural modulator of the fibril
spreading in the brain.
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Chapter 1 Introduction
1.1 Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative disease inflicting
approximately 5.4 million people in the US alone, according to the Centers for
Disease Control (as of Feb 2018). This number is projected to increase
dramatically with the aging baby-boomer population. AD manifests itself in the
form of dementia and can cause symptoms such as memory loss, difficulty with
time and space, and challenges completing every-day tasks at home. This
disease is histopathologically hallmarked by inclusions comprised of two different
protein aggregates [1]. The first type of aggregate is called a senile plaque, and
is composed of a protein fragment named amyloid beta (Aβ) [2]. This fragment is
the product of abnormal proteolytic processing of the amyloid precursor protein
(APP) [3]. The other proteinaceous component that is associated with AD is
called a neurofibrillary tangle (NFT) [4]. NFTs are part of a larger structure called
an intraneuronal lesion [5]. These lesions are comprised primarily of amyloid
fibrils made of phosphorylated Tau protein [4].
In AD, Tau pathology begins in the locus coeruleus in the entorhinal cortex
and spreads through the brain to eventually be found in nearly every region in the
later stages [6]. This pathology and subsequent neurodegeneration can be
1

accelerated by genetic mutation [7], trauma [8] ̶ [9], and unknown mechanisms.
The stages of the NFT spread are described as Braak Stages [1], [10]. Braak
stages I and II are when NFT involvement is primarily in the entorhinal cortex
region of the brain. Stages III and IV possess the characteristics of earlier stages
as well as the spread to limbic regions such as the hippocampus. The final
stages V and VI are used to describe the extensive neocortical NFT deposition in
the advanced disease state.
1.2 Tauopathies: a class of protein misfolding diseases
Deposition of aggregated Tau protein is also found in over twenty other
neurodegenerative diseases (besides AD), collectively named Tauopathies. The
list of Tauopathies includes diseases such as; chronic traumatic encephalopathy
(CTE) [11], corticobasal degeneration, progressive supranuclear palsy (PSP),
and a type of Frontotemporal Dementia also known as Pick’s disease (for a
thorough review see [12]). AD is the best studied and most common variant of
these diseases. CTE received more attention recently due to the fact that several
high-profile professional athletes have been diagnosed post-mortem with the
disease [13]–[15]. This emergent disease demonstrates our fundamental lack of
knowledge in this area and how traumatic brain injury can lead to unusual
pathology in the brain.
1.3 Microtubule associated proteins
Proteins are comprised of linear chains of amino acid building blocks that
typically fold into biologically important three-dimensional (3D) structures. These
2

3D structures can perform very specific reactions in the cell, but not all
biologically important proteins are folded. There is a class of proteins called
intrinsically disordered proteins (IDPs). These proteins contain no regular
structured regions and are less common than their folded or partially folded
counterparts. Disorder in proteins is common, however. For example, 97% of
proteins are predicted to have disorder in the first or last five residues in the
chain [16]. An example of this are histone proteins that bind and organize DNA in
eukaryotes [17].
Although the two-main microtubule associated proteins (MAPs) discussed
here, MAP Tau and MAP2 are considered IDPs, they are not completely devoid
of structure. Studies show that MAP Tau monomer is not a random coil but rather
a loosely associated hairpin structure [18] ̶ [19]. Structural studies have utilized
Förster resonance energy transfer (FRET) experiments to demonstrate that the
N-terminus and C-terminus of Tau are in close proximity to each other, and to
other key residues tested in the microtubule binding repeat (MTBR) region [20].
Due to the apparent backfolding of the ends of the protein, Tau resembles a
paperclip. However, these regions do not have regular secondary structure in the
traditional sense, except for small transient folds that do not persist for long
periods of time in solution [19] ̶ [20].
The other MAP of interest for this work, MAP2, is also considered
intrinsically disordered, except for a small sequence in the amino terminal
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domain that is implicated in binding to the regulatory subunit of protein kinase A
[22].
Native functions
Microtubule associated proteins are a critically important set of proteins
that have been shown to stabilize [23] and crosslink [22] ̶ [23] microtubules in a
healthy mature neuron. This stabilization effect is attributed largely to the
interaction of the microtubule binding repeat region (MTBR, Fig 1.1) with the
negatively charged microtubule surface. Microtubule stabilization in the axon is
very important as microtubules are one of the main structural components
involved in membrane protrusion [25]. Tau and other MAPs are key regulators of
microtubule dynamics. The interactions between Tau and microtubules are
controlled in part by the phosphorylation state of Tau (see below). The most
common amino acid in these repeats is the lysine residue which is a major
contributor to the electropositive nature of these repeat regions. MAPs perform
their native functions by binding to microtubules through electrostatic interactions
in these MTBR regions. The charges are well distributed along the MAP
backbone resulting in heat stability [26] and this contributes to the stable randomcoil structure required for function in the cell.
Tau Isoforms and splicing
The best studied of these MAPs is MAP Tau. The MTBRs are comprised
of either 3 or 4 imperfect repeats consisting of either 31 or 32 amino acids and
are present in all isoforms of MAPs expressed in humans [27]–[29]. This feature
4

is what gives rise to the naming half of the isoforms three-repeat (3R) and the
other half the name four-repeat (4R). The presence of the second repeat is
determined by alternative splicing of exon 10 in the MAPT gene. Tau protein can
be further categorized by whether exons 2 and/or 3 are spliced. This results in
zero, one, or two N-terminal inserts in the protein. (Fig 1). With either 3 or 4
repeats and three different combinations of N-terminal inserts, there are 6
isoforms of Tau protein. All 6 are present in the adult human brain [30]–[32].

Figure 1.1 Scheme of Tau isoforms in humans. Tau protein exists in 6 splice
variants in humans. The variation is determined by whether exons 2, 3 or 10 are
expressed. Exons 2 and 3 encode the first and second inserts in the N-terminal
regions, respectively. Exon 10 is responsible for the second repeat in the
microtubule binding repeat region. K18 and K19 are constructs made of only the
MTBRs. The MTBRs are the primary component of Tau fibrils.
There are several other MAP homologues in humans including (but not
limited to) MAP1 A and B, MAP2 C and D, and MAP4. The other MAPs have
garnered less attention. This may in part be due to the isoform diversity. It has
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been demonstrated that MAP2 C and MAP2 D are present in neurons and are
localized primarily to the dendrites and cell body [33]–[35].
Phosphorylation and hyperphosphorylation
The phosphorylation state of MAP proteins has been shown to regulate
the binding affinity for the microtubule surface [36]–[39]. This is controlled tightly
in healthy cells by a variety of enzymes, such as microtubule associated protein
kinase (MAPK) [48] ̶ [49] and glycogen synthase kinase 3-β (GSK3β) [42]–[44].
In healthy individuals the average phosphorylation state is 2-3 mol PO43-/mol Tau
[45]. Tau becomes hyperphosphorylated [46]–[48] in disease (7-9 mol PO43-/mol
Tau), which reduces the affinity of Tau for the negatively charged microtubule
surface [49]. It is thought that the decreased net positive charge and higher
soluble concentrations of Tau help to drive aggregation in the cell.
1.4 Amyloids
Structure of amyloids
The amyloid structure is a class of protein fold often associated with
disease. Over 25 amyloid-forming proteins have been identified and associated
with serious diseases [50]. Amyloids are characterized as fibrillar protein
structures, typically with a cross-β-sheet structure where parallel chains of βstrands are arranged perpendicular to the fibril axis (Fig 1.2). X-ray fiber
diffraction studies yielded basic information about the spacing between β-strands
and β-sheets [51]–[53]. Continuous wave (CW) electron paramagnetic resonance
(EPR) spectroscopy has given insight into the core structure of Tau fibrils [54]–
6

[58] and other amyloids [59]–[61] by demonstrating that the stacked monomers
in the fibril adopt a parallel and in-register structure. Amino acids are stacked on
identical residues from the next monomer layer along the fibril axis (Fig 1.2 B).

Figure 1.2 Model of amyloid fibril structure. A Amyloid fibril structures are
comprised of β sheets with sheet-sheet packing. Each monomer layer is
separated by 4.8 Å. B Stacking of monomers is in parallel and in-register fashion.
Individual residues are stacked in the fibril along the long fibril axis directly on top
of the identical residue in the adjacent monomer (indicated by the blue star).
Another EPR technique used in structural studies of amyloid fibrils is
called double electron-electron resonance (DEER) spectroscopy [61]–[64]. This
has been used to measure the distance between a fixed pair of nitroxide spin
label radicals, introduced at known positions on the protein backbone [59] ̶ [61].
Multiple distances may arise in the analysis, which can be attributed to an
ensemble of conformers [58], [63] ̶ [64], [66]. Nuclear magnetic resonance has
had success in studying the structure of these fibrils [67]–[70]. CryoEM provided
atomic-level resolution and illustrated which repeats in Tau are involved in the
core of the fibrils from a patient with Alzheimer disease [71].
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Amyloid formation
Conversion of soluble protein to insoluble fibrillar aggregates is still poorly
understood. Amyloid formation generally comes with the loss of native function of
the protein or peptide [72]–[75] and can include toxic species along the
aggregation pathway [76]–[78]. Aggregation is thought to proceed through the
formation of a nucleus that can turn into a small soluble oligomer, which can
mature into an insoluble fibril (Fig 1.3) [79]–[83].

Figure 1.3 Amyloid aggregation pathway scheme. Although the exact mechanism
of action and structure of oligomers is unknown, studies show it is the small, still
soluble species, that are toxic to cells [84]–[88].
The structure of early pathway aggregates is difficult to study with
techniques commonly applied to other proteins, such as X-ray crystallography.
There have been attempts at studying the early stages of the Tau aggregation
pathway, however [89]. In the case of oligomers, less is known about their
structure, but it has been demonstrated that toxic species in the aggregation
8

pathway are oligomers [90]–[92]. One problem with the study of oligomers is
trying to discern which size or stage of these oligomers are toxic but it has been
shown that small aggregates can propagate through neuronal networks [93]–[96].
This leads to toxicity because the process of templating in a new cell can begin
when the small fibrils are internalized in the neighboring cell [93], [97]–[99].
Therefore, a method by which to study these structures is essential.
1.5 Conformation and conformational ensembles of Tau amyloids
The conformation of amyloids depends on the initial nuclei that form [50].
These nuclei drive aggregation by templating the exact same misfolded state
onto the endogenous population [55], [100]. It follows that different sets of nuclei
may form in a disease, which could result in the pathology and progression of
that disease. It has been shown that the conformation of Tau fibrils can be
modulated by single mutations [58]. This means that conformational
incompatibilities arising from sequence changes in monomers can drive the
structure of these fibrils and that they can evolve over time.
Under conditions in the lab it may be possible to form multiple fibril
conformations simultaneously. There are usually a dominant species and subspecies of conformers. These conformational ensembles can evolve resulting in
new dominant species [58], [64]. Multiple conformers might also form in the
brains of people afflicted with amyloid disease. As the fibrils spread from regionto-region [94] ̶ [95], selection pressures exerted on the fibril species may change.
Although the mechanism is unclear, selection pressures may change with
9

respect to post-translational modifications [48], [87] or mutations of endogenous
protein [57], [96] ̶ [97], for example. This may result in an altered conformational
ensemble that favors the new conditions.
1.6 Diagnosing, preventing, and treating AD
There is no cure for AD on the market. Many treatments are ineffective by
the time the disease is diagnosed. Although recent developments show promise
[103] ̶ [104], there are no antemortem diagnosis methods for AD or other
Tauopathies besides neurological examinations[107] and cognitive testing [108]–
[111]. The onset of Tau hyperphosphorylation and mild cognitive decline [112] is
years before these diagnostic methods can provide an accurate diagnosis. The
focus of treatment has been in the development of inhibitors to aggregation
[113]–[115]. Drugs are generally administered late in progression and are not
effective at reversing the disease [116]–[118]. These critical areas of research
have been slowed by the lack of structural data available and by the sheer
challenge of the problem. Treatment would likely be more effective if
administered early, highlighting the need for a rapid and early detection method.
1.7 The scope of my research
I examined several aspects of MAP Tau aggregation. These topics cover
monomeric Tau protein and its conversion into Tau protein aggregates. Explicitly
the topics include: monomer conformational heterogeneity, aggregation of Tau
monomers into fibrils, a study of Tau fibril conformation and conformational
selection processes and concludes with a study demonstrating that MAP2 is
10

capable of capping and blocking Tau aggregation in-vitro. These topics are
interlinked in that they all provide insight into the process in which healthy
monomeric Tau protein is converted into disease state-related Tau protein fibrils.
In Chapter 3 I examined the behavior of monomer species in solution.
This is important to understand because a conformational change in the
monomer is responsible for the nucleation behavior of Tau. Probing the structure
and elucidating monomer behavior may enable investigators to better understand
how the initial formation of fibrils occurs. I performed experiments in Chapter 4
which are evidence for the hypothesis that multiple conformations of Tau fibrils
exist in-vitro and that amyloid conformational ensembles can evolve. It is thought
that different conformations of Tau may form in different diseases, which could
drive their specific pathology. Tau fibril conformations may be the result of
different monomer conformations during the nucleation and oligomerization
process. If the various states of Tau in solution can be characterized, it may be
possible to elucidate which structure or structures contribute to various
Tauopathies, such as AD. In Chapter 5 I examined the stability of fibrils and their
associated cofactors once aggregation has taken place. Dissociative properties
of Tau monomers from the fibril must be such that the fibrils do not dissociate
upon breakage. If Tau fibrils dissociated spontaneously, it seems unlikely that
they would be capable of spreading. Lastly, understanding that Tau fibrils impart
their structure onto endogenous monomers may enable researchers to develop
therapeutics. One possible therapeutic avenue is to block the Tau monomers
11

from becoming incorporated on the fibril end. It is possible to block Tau
aggregation at the end of the fibril using a capping mechanism in-vitro. Lastly, I
demonstrate in Chapter 6 that the microtubule binding repeats of 3R and 4R
MAP2 block Tau aggregation and also that MAP2 is binding to the end of the Tau
fibril. Investigations of this blockage effect are being investigated in a cellular
system now. The study of the conversion of soluble Tau monomer to fibril
aggregates is one that is ongoing.
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Chapter 2 Methods
2.1 Tau constructs
The longest human 4R isoform, hT40wt, and the shortest 3R isoform,
hT23wt, were previously cloned into pET-28b plasmids using the NcoI/XhoI
restriction sites in the plasmid. Truncated constructs, K18wt and K19wt, were
also generated previously [56]. All mutagenesis was performed using the
QuikChange method to introduce different amino-acid substitutions. K18 with a
single cysteine on the N-terminus was synthesized and cloned by Biomatik using
NcoI/XhoI restriction sites in a pET-28 vector. Aligned constructs used for this
work can be found in Appendix A.
2.2 MAP2 constructs
Sequences for the microtubule binding repeats of MAP2 C and MAP2 D
(Uniprot #P11137 variant 5) were synthesized by Biomatik and cloned into pET28 vector using NcoI/XhoI restrictions sites. These constructs had the natural
cysteines replaced with serines (C404S and C444S). Constructs containing the
cysteines were generated using site-directed mutagenesis as per manufacturer’s
instructions as previously described. Also, a 4R truncated MAP2 N-terminal
cysteine construct was synthesized and cloned by Biomatik into a pET-28 vector
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using NcoI/XhoI restriction. Aligned constructs used for this work can be found in
Appendix A.
2.3 Plasmid transformation and DNA purification
Plasmid DNA was transformed into BL21 (DE3) cells (Agilent) or XL1-Blue
cells (Agilent) for protein expression or DNA amplification purposes, respectively.
Transformation was performed as follows, cells were thawed on ice and 25 µL of
thawed material was transferred to a 14 mL round bottom polypropylene tube
(Corning Falcon). Two microliters of pure DNA were combined with cells and
allowed to sit on ice for 30 minutes. Cells were permeabilized by heat shock at
42 °C for 45 seconds and then placed on ice for 2 minutes, then 500 µL of NZY+
(10 g/L NZ-amine, 12.5 mM MgCl2, 12.5 mM MgSO4, 20 mM glucose) media was
added and the cells were allowed to incubate at 37 °C for 45 - 60 minutes.
Volumes of incubated material were plated on kanamycin plates at either 25-50
µL for purified DNA or 250-500 µL for PCR product.
Plasmid MIDI preparations were performed according to the
manufacturers (QIAGEN) instructions. High-copy XL1-Blue cells were
transformed with DNA, as above, from either site-directed mutagenesis reactions
(Agilent) or previously purified DNA.
Mammalian plasmid MIDI preparations were performed according to
manufactures instructions (Omega). DNA was eluted with prewarmed (40 °C)
PCR grade H2O. Eluent was repassed through column to achieve the highest
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concentration. DNA was quantified using A280 nm and purity assessed via the ratio
of A260 nm / A280 nm.
2.5 Recombinant protein expression
Protein expression was performed as follows; previously transformed
BL21 (DE3) cells were scraped from either a kanamycin plate or a previously
prepared glycerol stock and added to 50 mL of LB (20 g/L, Difco) with 20 µg/mL
Kanamycin (Gold Bio). The solution was incubated at 200 RPM and 37 °C for 1618 hours to produce a starter culture. The resultant culture was mixed with 1.5 L
of LB at a ratio of 1:100 supplemented with 20 mg/L Kanamycin (Gold Bio) and
incubated at 200 rpm and 37 °C until the OD600 nm = 0.8 - 1.0. Protein expression
was induced with 0.5-1 mM IPTG for 3.5 hours at 37 °C and 200 rpm. The cells
were harvested at 5500 x g for 10 minutes. Pellets were taken up in 500 mM
NaCl, 20 mM piperazine-N,N’-bis(2-ethanesulfonic acid (PIPES, JT Baker or
RPI) pH 6.5, 5 mM ethylenediaminetetraacetic acid (EDTA, Fisher), 50 mM 2mercaptoethanol (Fisher, electrophoresis grade), and stored at -80 °C.
2.6 Protein purification
Bacterial pellets from previous step were thawed for 20 minutes at 80 °C
to precipitate heat insoluble protein. Samples were sonicated on ice at 50%
power for 1 minute with a tip sonicator to lyse the cells and release soluble
protein. Lysis solution was centrifuged at 20,000 x g for 30 minutes to remove the
insoluble cellular material. The supernatant was adjusted to 55% (w/v)
ammonium sulfate and rocked for 1-16 hours in order to precipitate the remaining
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soluble protein. Precipitated protein was collected by centrifugation at 4,000 x g
for 10 minutes. The supernatants were discarded, and the pellets were respun at
the same settings. The remaining supernatant was pipetted off and the pellets
were taken up in 8 mL of either nanopure water (Tau) or 10 mM PIPES pH 6.5
150 mM NaCl 2 M urea (MAP2 proteins) both supplemented with 4 mM DTT.
Additional buffer, salt, and urea was added due to low MAP2 solubility. Samples
were combined and sonicated for 1 minute at 50% power to shear DNA and
disrupt any small aggregates. These sonicated samples were syringe filtered
(Pall Acrodisc 0.45 µM) to remove any particulate and diluted until conductivity
was below 20 mS/cm. Protein was loaded onto a cation exchange column (Mono
S 10/100 GL, GE Healthcare) using 50 mM NaCl, 20 mM PIPES, 0.5 mM EDTA
and eluted with a linear gradient of 1 M NaCl, 20 mM PIPES, and 0.5 mM EDTA.
Protein was pooled based on an SDS-PAGE, adjusted to 3 mM DTT, and stored
at 4 °C for immediate use or -80 °C for future use. Samples were loaded onto a
S75 column (GE Healthcare) for truncated Tau or an S200 column (GE
Healthcare) for full length Tau or MAP2 proteins to separate proteins by size.
Fractions containing protein were pooled based on UV trace and precipitated
overnight as follows; truncated Tau was mixed 1:4 with Acetone (Fisher, Optima
Grade) and full length Tau was mixed 1:1 with methanol (Fisher Optima Grade),
all were adjusted to 4 mM DTT and incubated overnight at 4 °C. Precipitated
protein was collected by centrifugation at 12,000 x g for 10 minutes. Protein
pellets were stored at -80 °C under 2 mM DTT (acetone or methanol for
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truncated and full-length Tau, respectively) until further use. Representative
chromatograms for purification of K18 and MAP2 are attached in Appendix C.
2.7 Protein monomerization
Pellets from previous step were washed three times with either acetone
(truncated proteins) or methanol (full length proteins) devoid of DTT and all
supernatant was removed each time with a gel loading tip. Protein was dissolved
in 8 M guanidinium HCl (Thermo) for 2-24 hours. No more than 300 µL of
dissolved protein was loaded onto a PD-10 desalting column (Ge Healthcare)
equilibrated with assembly buffer (10 mM HEPES pH 7.4 100 mM NaCl 0.1 mM
NaN3), and 2.0 mL of this assembly buffer less volume of dissolved protein was
added and allowed to flow completely through. To elute protein, 2.0 mL of
assembly buffer was added to the column and collected for BCA (Pierce)
quantification which was performed according to manufacturer’s instructions.
2.8 Protein (cysteine residue) conjugation reactions
Cysteines in Tau or MAP2 were covalently conjugated with a variety of
labels for this work. Either a single natural residue (C291 or C322 in Tau or C409
or C440 in MAP2, numbered according to Uniprot # P11137, variant 5) or an
unnatural cysteine introduced through site-directed mutagenesis or in a construct
ordered commercially (Biomatik) were labeled using maleimide (PEG-Biotin,
Alexa, and Atto conjugates) conjugation reactions. Briefly, cysteine containing
protein pellets dissolved completely in 8 M guanidinium HCl were conjugated by
adding a 10:1 molar excess of dye to protein. This reaction was mixed thoroughly
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and allowed to proceed for 2-24 hours in the dark. Excess dye and guanidinium
was removed using a PD-10 desalting column (GE) and protein eluted as
described above. Protein concentration was determined using BCA (Pierce)
according to manufacturer’s instructions. Fluorescent labeling efficiency was
determined using protein diluted to 1 µM according to BCA and measuring dye
absorbance in a Cary 100 UV-vis spectrophotometer. Absorbencies were
converted to concentrations using the Beer-Lambert Law. Extinction coefficients
that were used are as follows: Atto 647N (1.5 x 105 M-1cm-1), Atto 633 (1.3 x 105
M-1cm-1), Alexa 488 (7.3 x 104 M-1cm-1), Alexa 594 (9.2 x 104 M-1cm-1).
2.9 Fibril formation
Fibrils were formed by combining 25 µM Tau and 50 µM heparin (Celsus,
average MW 4400 kDa) in 100 mM NaCl 10 mM HEPES pH = 7.4 (referred to as
assembly buffer from here on) to induce aggregation of monomer. 0.5 mM TCEP
was included if cysteines were present to provide a reducing environment.
Solutions were made at volumes of at least 500 µL and were stirred for 3 days for
truncated Tau and 8 days for full length Tau at room temperature (22 °C) using a
Barnstead Thermolyne stir plate set to 220 RPM.
2.10 Seeded reaction
Stirred fibril material was sonicated using a Fisher Sonic Dismembrator
Model 100 with power set to 20% for 30 – 120 seconds, depending on the
application. Seeded reactions were performed by combining 10 µM fresh
monomer and 20 µM heparin to induce aggregation (and 0.5 mM TCEP if
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cysteines were present in monomers) with 2 – 10% monomer molar equivalents
of sonicated preformed fibrils added to serve as seeds. Monomers were allowed
to template and elongate the fibrils for 6 hours. Reactions were ultracentrifuged
at 130,000 x g. Pellets (insoluble fraction) and supernatants (soluble fraction)
were separated, pellets were resuspended in equivolume (with respect to
reaction volume) of 1 X Laemmli sample buffer, and both were analyzed using
SDS PAGE (15% for truncated and 12% for full length).
2.11 Consecutive seeding cycle experiment
Consecutive seeding cycles were performed as follows. Fibrils stirring for
three days were sonicated 30 seconds at 20% power using a Fisher Sonic
Dismembrator Model 100 to generate small fibrillar seeds and added in 10%
monomer molar equivalents to 25 µM Tau, 50 µM Heparin in assembly buffer at
a final volume of 500 µL. Cycle one was incubated for 1 hour at 37 °C and
subsequently sonicated and used as seeds in the second reaction. This process
was repeated until the ninth or fourteenth cycle was reached at which point the
monomer concentration was increased to 50 µM Tau, heparin concentration was
reduced to 12.5 µM, and seeds were added at 5% molar monomer equivalents.
50 µM reactions of cycle 1 (from original seeds), cycle 5 (from cycle 4), cycle 10
(from cycle 9), and cycle 15 (from cycle 14) were allowed to reach completion
overnight at 37 °C.
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2.12 Breakage sensitivity
50 µM overnight reactions of cycle 1 or cycle 10 samples from consecutive
seeding cycle experiments (above) were subjected to 60 seconds of sonication in
a QSonica bath sonicator at 5% power, subsequent fibril fragments were diluted
to 10 µM and prepared for transmission electron microscopy analysis (below).
2.13 Transmission electron microscopy sample preparation and ImageJ
analysis
Concentration of Tau was adjusted to 10 µM total protein using assembly
buffer and loaded onto Formvar carbon coated Cu grids by resting the grid on a
10 µL droplet of protein on parafilm for 60 seconds. Excess protein was blotted
gently on Whatman filter paper and the grid was placed on a 10 µL droplet of 2%
uranyl acetate (Electron Microscopy Sciences) for 60-120 seconds. Grids were
blotted and allowed to dry for 10 minutes on filter paper. Images were taken on a
Tecnai F12 Biotwin scope using 100 kV high tension on a Gatan camera at
University of Colorado, Boulder.
Fibrils were analyzed by ImageJ (NIH version 1.8.0) for length, width, and
helical periodicity. The scale was set by measuring the length of the scale bar
(153 pixels) and setting the scale in ImageJ to 100 nm. Data sets were collected
in ImageJ, sorted in Excel (Version 1801) and plotted in GraphPad (Version
7.04).
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2.14 Fibril dissociation experiments
Fibrils formed with RNA were made by stirring 25 µM Tau and 12.5 µg/mL
PolyA RNA (Sigma, product number P9403, lot 084M4144V) in assembly buffer
for three days at 22 °C. Fibrils were subsequently diluted 1:5, 1:10, 1:20, and
1:40 with assembly buffer and incubated for 12 hours in the absence or presence
of 50 µg/mL PolyA RNA.
Fibrils formed with RNA were adjusted to 500 mM NaCl and incubated for
15 minutes at room temperature. The reaction was ultracentrifuged in order to
separate insoluble pellet (fibril) from soluble supernatant (monomer). The pellets
were then either taken up in 1 X Laemmli buffer for SDS PAGE analysis or taken
up in 60 µL 2% sodium dodecyl sulfate (SDS). Pellet samples dissolved in 2%
SDS and supernatants were brought up to 1250 µL in assembly buffer (10 mM
HEPES pH 7.4 and 100 mM NaCl) and measured on a Cary 100 for absorbance
at 280 nm. Triplicates were measured, averaged and standard deviation was
plotted in Excel.
2.15 ThioflavinT kinetics
ThioflavinT (ThT) kinetics were measured by combining 10 µM monomeric
Tau, 20 µM heparin, 0.5 mM TCEP (if cysteines present), 5-20 µM ThT, and 210% seeds (monomer molar equivalent) in assembly buffer and measured on a
Tecan M1000 or Omega Fluorstar fluorescent plate reader. Excitation was
performed at 440 nm and emission of ThT was monitored at 480 nm for 3 - 10
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hours. Data were exported to, and averages of replicates were plotted in, Excel
showing either SD or SEM error bars.
To measure ThT kinetics of nucleation, fluorescence was measured in an
Omega Fluorostar plate reader. Excitation was performed at 440 nm and
emission of ThT was monitored at 480 nm. 25 µM Tau monomer and 50 µM
heparin cofactor mixtures were incubated quiescently in a sealed 96 well plate at
37 °C. To ensure the reactions were fully mixed, plates were shaken once for 3
seconds at 100 RPM at the beginning of the experiment.
2.16 Proteinase K sensitivity assay (limited proteolysis)
Reactions of cycle 1 or cycle 10 fibrils formed in consecutive seeding
cycle experiment (above) were subjected to limited proteolysis by 7 nM or 70 nM
proteinase K for 1 hour at 22 °C. Proteolysis was stopped by addition of 4 mM
phenylmethyl sulfonyl fluoride (PMSF) and Laemmli sample buffer to a final
concentration of 1x.
2.17 Turbidity analysis
Consecutive seeding cycle reactions of K18 or K19 (above) were
measured at 340 nm for light scattering on a Cary 100 UV-vis
spectrophotometer. Measurements were taken in biological triplicate and
averages plotted with SEM reported.
2.18 MAP2 blockage experiment
Seeded reactions were performed as above with the addition of
monomeric MAP2 proteins at substoichiometric concentrations. Briefly, 10 µM
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Tau protein and 20 µM heparin were added to serially diluted MAP2 protein at
either 5, 2.5, or 1.3 µM final concentration and 10% seeds were added to induce
Tau aggregation. Reactions were incubated at 37 °C for 6 hours and thereafter
centrifuged at 130,000 x g for 30 minutes. Pellets were separated from
supernatants and dissolved in equivolume (with respect to supernatant) of 1 x
Laemmli sample buffer and run on 15% SDS-PAGE with pellets and
supernatants. Gels were stained with Coomassie-R250. Scanned gels were
analyzed by band densitometry on ImageJ and quantified band intensities were
plotted in GraphPad. Plotted data was analyzed by one-way ANOVA in
GraphPad.
2.19 Atto 647N and 633 fluorescence anisotropy of MAPs
Fluorescence anisotropy of truncated Tau and MAP2 was performed with
protein labeled at the natural cysteine in the third repeat (322 for Tau or 440 for
MAP2 (numbering described above)) with Atto 647N and 633 (AttoTek). 50 µM
Tau monomer was added to 5% preformed K18 fibrils with 6.3 µM Heparin (8:1
ratio) were incubated for 16 hours overnight and sonicated for 2 minutes at 20%
power and these fibrils were titrated into a solution containing 100 nM Atto
labeled protein. When vertically polarized light is used to excite a fluorophore,
fluorescence anisotropy (r) can be determined by the following equation[119] :

𝑟=

𝐼𝑉𝑉 − 𝐼𝑉𝐻
𝐼𝑉𝑉 + 2𝐼𝑉𝐻
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Equation 1 Fluorescence anisotropy. IVV is the intensity of vertically polarized
fluorescence emission and IVH is the intensity of horizontally polarized
fluorescence emission.
Fluorescence emission intensities are measured using parallel (IVV) and
perpendicular (IVH) filters, with respect to the excitation. Polarization biases
introduced by the instrument can be accounted for by applying a grating factor, or
G-factor. The G-factor is determined by the following quotient:

𝐺 =

𝐼𝐻𝑉
𝐼𝐻𝐻

Applying the G-factor to the previous equation gives:

𝑟=

𝐼𝑉𝑉 − 𝐺𝐼𝑉𝐻
𝐼𝑉𝑉 + 2𝐺𝐼𝑉𝐻

Fluorescence was initiated with excitation of polarized light at 610 nm (slit
width = 2 nm). Fluorescence emission anisotropy readings were measured at
630 nm (slit width = 4 nm). This process was repeated 10 times and averaged on
a Horiba Jovan Fluorolog spectrometer for each sample. Each data point was
performed in triplicate using independent batches of seeds and those values
were averaged and plotted with SD in GraphPad. Fits were added in GraphPad
for one site total binding and KD values were taken from this analysis.
2.20 Alexa 488/594 Förster resonance energy transfer
50 µM Tau monomer was added to 5% seeds and 6.2 µM heparin and
incubated at 37 °C for 16 hours. 500 µL of this reaction was sonicated for 2
minutes at 20% power to produce small fibril seeds. 10 µM seeds were added to
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1 µM K18 labeled on the N-terminus with Alexa 488 and incubated at 37 °C for 1
hour to allow for templating of labeled protein on the fibril. The samples were
measured by excitation at 450 nm and collecting emission spectra from 500-675
nm. Excitation and emission slit widths were set to 5 nm. This was followed by
addition of 1 µM protein labeled on the N-terminus with Alexa 594 as an acceptor
dye (Tau Alexa 594, truncated 3R MAP2 Alexa 594, or truncated 4R MAP2 Alexa
594). These reactions were incubated for another 1 hour at 37 °C. Following
incubation with the acceptor species, samples were measured again by
excitation at 450 nm and collecting the emission spectra of the samples from
500-675 nm. Spectra were averaged in biologic triplicate and plotted with SEM
reported in Excel.
2.21 Streptavidin-conjugated magnetic bead pulldown
250 µL of 20 µM PEG-Biotinylated (Thermo product # PI21911) Tau or
MAP2 was rotated at 40 rpm with 200 µg of hydrophilic streptavidin conjugated
magnetic beads (NEB product number S1421S) for 60 minutes. Beads were
pulled to bottom of tube with a powerful magnet (see appendix B). Bead pellet
was rinsed thoroughly with 1000 µL of assembly buffer and beads were pulled to
the bottom of the tube again. The beads were then resuspended in 250 µL
assembly buffer containing 5 µM preformed K18 fibrils and rotated again for 60
minutes. Beads were collected and washed again with 1000 µL of assembly
buffer. Finally, beads were taken up in 50 µL of 1x Laemmli sample buffer and
heated at 95 °C for 10 minutes. Heating at 95 °C unfolds streptavidin and
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releases the biotinylated monomer and seed complex. Resultant sample buffer
solutions were run on 15% SDS PAGE and stained with Coomassie R250.
2.22 Gold nanoparticle labeling for TEM
25 µM K18 fibrils were sonicated for 60 seconds at 20% power and mixed
with 5 µM biotinylated MAP2 and allowed to incubate for 24 hours at
37 °C. Resultant solution was mixed 1:1 with streptavidin coated gold
nanoparticles (Aurion) at a final dilution of 1:40 for 90 minutes. These samples
were subsequently prepared for TEM analysis as described above.
2.23 Mammalian cell culture
Human embryonic kidney cells (HEK 293) were cultured in Dulbecco’s
Modified Eagle Medium (DMEM, Gibco) supplemented with 10% fetal bovine
serum (FBS, Gibco) at 37 °C and 5% CO2. For cells undergoing selection 400
µg/mL G418 (Gibco) was included in the media. Cells were subjected to a serial
dilution of G418 initially to establish a kill curve. Cells were dead within 7 days at
concentrations over 400 µg/mL. At 800 µg/mL cells died within 3 days.
In order to maintain cell cultures long term, the cells must be unadhered
from the plate and split. To achieve this, cells were washed with phosphate
buffered saline (PBS, Gibco) and enough trypsin reagent (TrypLE, Gibco) was
added to cover the plate. Cells were allowed to incubate for 3-5 minutes with
trypsin reagent and then were observed under an inverted microscope to assess
detachment. To break up any clumps, cells were forced through a pipette tip
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against the flask or dish bottom. The resultant solution of cells is split and either,
plated or put in a container with bleach for destruction.
In order to freeze mammalian cells, cryopreservant must be used to
prevent cellular damage during freezing. A 37 °C solution of 5% (v/v) sterile
dimethylsulfoxide (DMSO, Fisher Certified ACS grade, autoclaved) in FBS is
added to the suspension of unadhered cells, mixed, and aliquoted in 1 mL
cryogenic vials (Fisher # 10-500-25). These samples were slowly cooled to -80
°C by placing the tubes containing cells inside a Styrofoam container inside the
freezer. Once frozen, the cryobox (containing tubes) was placed in liquid nitrogen
for long term storage.
2.24 Transfection of human cells
Untransfected cells were grown to 20-40% confluency and media was
changed to 1% FBS DMEM 2-4 hours before transfection. Low serum media
proved to improve transfection efficiency without sacrificing health of cells during
incubation with the media. Transfection was achieved by using Lipofectamine
(Invitrogen) according to manufactures instructions. After 4-16 hours cells were
washed with PBS and placed back into DMEM containing 10% FBS for continued
culture.
2.25 Imaging transfected cells
Previously transfected cells were washed with PBS and placed in
OptiMEM. Imaging of cells was performed in 8 well plates (CellTreat), 96 well
plates (Corning Nunc), and 384 well plates (Greiner Bio). Cells were imaged for
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2-4 hours at a time and then placed back under 10% FBS DMEM to continue
culture.
2.26 Monoclonal line selection
Transfected cells were grown under selection media containing 400 µg/mL
G418 until 60-80% confluent. Cells were then passaged 1:20 and grown again
until 60-80% confluency (2-3 days) and then passaged 1:200 or 1:400 and plated
on 8 cm sterile glass petri dishes. Individual cells could be observed after several
days having grown into small (20-100 cells) colonies. These colonies were
observed under an inverted microscope and manually detached using a pipette
and placed into a 24 well polystyrene dish containing media and allowed to grow
for 0.5-2 weeks or until a large mat of cells developed. Cells were then split 1:6
and 5 x 1 mL aliquots were frozen using the technique described above. The last
1.0 mL was further diluted 1:1 with selection media and placed in either a T25
flask or split amongst wells of a plate for imaging.
These HEK cell experiments are ongoing and at the time of writing had not
produced final data. It is for this reason that the methods are included but there is
not representative data for these methods. The cell experiments were taken over
by Justin Shady.
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Chapter 3 Tau monomers exhibit conformational variation in solution
It has been previously shown that the toxic species in the aggregation
pathway of Tau protein is the soluble oligomer species [113] ̶ [114]. Studying the
conversion of monomeric Tau into toxic oligomers is therefore critically important
in order to understand the earliest stages of disease.
Monomeric Tau protein has been shown to be structurally dynamic in
solution. Circular dichroism measurements have shown Tau monomer adopts a
random coil structure [122]. Other studies show that Tau molecules have
intramolecular distances shorter than what would be predicted for a true random
coil. These results have led to a model where the regions flanking the
microtubule binding repeats fold back and adopt a paperclip-like structure [20].
These studies typically examine freely-diffusing proteins in solution. The
measurements are typically characterized by poor signal-to-noise and short
windows of measurement. In order to overcome this limitation, we established a
collaboration with the Goldsmith group at the University Wisconsin, Madison.
This group employs an antibrownian electrokinetic (ABEL) trap [123]–[125] to
monitor individual molecules for timescales on the order of seconds. The ABEL
trap, a microfluidic fluorescence measurement instrument is capable of tracking
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the position of single fluorophores and utilizes real-time feedback voltages to
push individual molecules (here proteins) back to the center of the measurement
cell. This allows for fluorescence measurements to be taken for multiple seconds
[120] ̶ [121]. Histograms of fluorescence anisotropy data are subsequently
detailed enough to represent monomeric conformational heterogeneity in
solution. Here an ABEL trap is used to examine Tau monomer for conformational
variability in solution. This represents the first use of an ABEL trap on an IDP
[127].
Fluorescence anisotropy measurements can be used to examine the
rotational freedom of fluorescent molecules in solution. When the fluorophore is
attached to a protein, it is possible to study the solution-phase behavior of the
protein. Polarized light can be used to selectively excite electrons in fluorescent
molecules whose excitation dipole is aligned with the incoming polarized light.
Fluorescence anisotropy is a measurement of the depolarization of the emission
dipole in a fluorescent molecule, relative to the polarization of the incident light
used to excite the molecules. As molecules rotate and diffuse in solution, the
emission dipole’s position in space will change relative to the original
directionality of the dipole when it was excited. Fluorescence anisotropy can be
calculated by measuring the emission spectra intensities using parallel and
perpendicularly aligned polarizers with respect to the polarized light used for the
excitation (see equation in section 2.19). Because fluorescence is a short-lived
process (on the order of ns), anisotropy measurements can provide a snapshot
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of the tumbling of fluorescent molecules. If the molecules are not rotating in the
time frame of fluorescence emission, the maximum value for anisotropy is 0.4.
Molecules whose emission dipole dephases 90° (that is, aligns with the
perpendicularly aligned polarizer) during the fluorescence lifetime, have a
minimum value of -0.2.
Fluorescence anisotropy measurements were taken of full-length human
Tau protein (hTau40). In order to utilize maleimide chemistry (and only label 1
position), the two native cysteines were removed and replaced with serines
(C291S/C322S). A cysteine was introduced with site-directed mutagenesis at
position 310 (Y310C). This single cysteine mutant was labeled with Atto 647N
and Atto 633 for fluorescence anisotropy measurements in the ABEL trap.
Additionally, the Goldsmith group at UWM labeled commercially available
microbial transglutaminase (MTG) with ATTO 647N. This globular enzyme
contains one native cysteine in its active site and has a relatively similar
molecular weight (Fig 3.1 A – B).
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A

B

Figure 3.1 Structure for proteins used in this work. A hT40 based on [20], [21]
and B Microbial transglutaminase (MTG) based on [128].
In order to study the aggregation pathway of Tau monomer using the
ABEL trap, it first must be shown that the protein can be studied using this
instrument and methodology. The ABEL trap measurements begin with the
feedback voltages off (left side of Fig 3.2 A-E, denoted by off). Feedback
voltages are responsible for pushing charged species in the microfluidic
measurement in order to trap them for prolonged measurement. Then, upon
application of the feedback voltages, fluorescence intensity and anisotropy
measurements are taken (Fig 3.2 A – E black trace with red fit trace).
Fluorescence anisotropy measurements of Atto 647N conjugated to hT40 were
recorded (Figure 3.2 A scale on the right of the graph). Anisotropy of trapped
hT40 was observed to be approximately 0.2 (Figure 3.2 A blue trace) and
anisotropy for trapped MTG labeled with 647N was 0.3 (Figure 3.2 B blue trace).
These results initially contradict intuition. The globular folded nature of MTG
would suggest it should be more compact than Tau and should rotate more
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quickly than the unfolded Tau molecule. The only native cysteine in MTG exists
inside the folded protein structure. The fluorophore is conjugated to this cysteine
inside the core of the folded protein. This results in limited rotational freedom of
the dye and its C5 linker. Therefore, reduced depolarization and higher
anisotropy are observed despite the protein being in a compact, freely rotating,
and folded state. Upon denaturation in 6 M guanidinium HCl (GdmCl), the MTG
molecule had a marked decrease in anisotropy (0.2), nearly identical for the
unfolded Tau molecule (Figure 3.2 C). This is a result of the increased rotational
freedom allowed by the unfolding of the protein. Several components can
contribute to the reduced anisotropy observed for fluorescent molecules attached
to unfolded proteins. The C5 linker which separates the fluorophore and protein
backbone would have increased rotational freedom in an unfolded protein. This
results in greater depolarization than in the case for the folded enzyme.
Additionally, the increase in random motion of the protein backbone would add to
the depolarization of the fluorescence emission. This is because solvent exposed
fluorophores will have additional freedom to rotate when compared to the active
site of the folded enzyme. This result supports previous observations that Tau is
largely unfolded. Finally, it was shown that free dye (hydrolyzed) in 50% glycerol
has a similar anisotropy to that of the denatured proteins (Figure 3.2 D). These
results suggest the fluorescence anisotropy being measured is not an artifact
caused by the dye binding to the inner walls of the microfluidic device or other
proteins. Protein clumping can be eliminated as a cause for the fluorescence
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anisotropy values observed. Emission values would be multiplied by n, where n
is the number of proteins clumped together. This was not observed, however.

Figure 3.2 Representative traces for molecules in the ABEL trap. A) htau40‐
ATTO647N, B) MTG‐ATTO647N, and C) MTG‐ATTO647N denatured with 6 M
guanidinium chloride (GdmCl) were trapped in solutions with 25 % glycerol. D)
Hydrolyzed ATTO647N was trapped in buffer with 50 % glycerol. Fitting change
points in the trapping data are shown in red (left axis), and anisotropy is shown in
blue (right axis). Feedback voltages off (left of bar at 2 seconds) and on (right).
Trapping data was collected by Lydia Manger at UWM.
The results of many trapping events were binned and plotted as
histrograms of anisotropy vs frequency (Fig 3.3). Anisotropic values of 679
trapping events for fluorescently labeled hT40 were fit with Gaussian functions.
Tau data was best fit with two Gaussian functions and is bimodal (Fig 3.3 A). The
fluorscent anisotropy data for Tau suggests there are at least two populations in
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solution, compact and extended forms. 253 trapping events for MTG were fit with
one narrow Gaussian function and these results are consistent with a single
globular fold for the enzyme (Fig 3.3 B). Tau and MTG were then measured in
the presence of 6 M GdmCl. Addition of denaturant should disrupt the folded
protein structure in solution. Upon denaturation, the bimodal distribution for Tau
becomes a wide single-distribution and the peak for MTG shifts to lower
anisotropy (Figure 3.3 C and D). The results match expectations since Tau has
been shown to adopt a paperclip-like structure in solution [20], and upon addition
of denaturant, the loose structure of Tau should be peturbed. The unfolded
proteins exhibit higher rotational freedom around the C5-linkers between the dye
and the protein backbone. This allows for lower anisotropy values despite the
protein backbone becoming unfolded and tumbling more slowly. It is necessary
to add glycerol to these samples in order to improve trapping by slow molecular
diffusion. The fluorescence anisotropy of hydrolyzed (free) dye was determined
to be 0.18 in 50% glycerol (Figure 3.3). By addition of 80% glycerol (v/v),
anisotropy increased to 0.29, indicating the more viscous solution slowed
rotational freedom. This slowing is demosntrated by the decrease in emission
dipole depolarization, which is due to the increased viscocity of the 80% glycerol
solution.This anisotropic behavior models the folded and unfolded states of the
proteins. This also suggests the dye is freely diffusing and its diffusion was
slowed by the additional solution viscocity.
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Figure 3.3 Single molecule anisotropy histograms vs probability showing bimodal
distribution for only hT40. A hT40 Atto647N exhibits two populations in the
fluorescence anisotropy measurements. B Folded microbial transglutaminase
(MTG) exhibits one tightly distributed fluorescence anisotropy histogram. C hT40
in the presence of 6 M guanidinium HCl (GdmCl) no longer exhibits two
populations. This suggests that intermolecular interactions were disrupted upon
addition of the denaturant. D MTG in the presence of 6 M GdmCl has a wider
distribution and a lower anisotropy suggesting that the unfolded state has greater
emission depolarization due to an increase in rotational freedom of the attached
dye. E Hydrolyzed (free) dye in solution at two different glycerol concentrations.
This suggests the shift in anisotropy is not due to trapping artifacts. Histograms
were prepared Lydia Manger.
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These results are indicative that Tau possesses at least two solutionphase families of structures. It is likely the Tau monomer is capable of sampling
various transient states within these families. This is demonstrated by broadening
of the fluorescence anisotropy distributions of Tau monomer. Whereas the folded
MTG distribution is narrow due to limited conformational sampling and
compactness of the enzyme’s active site. The families of Tau monomer
structures can be broadly defined as compact and extended. This data also
suggests that Tau exists in dynamic equilibrium between the two states. The
structures of Tau monomer interconvert from one population to the other, but not
on the timescales observed here. The Gaussian fit distributions are broad and
overlapping suggesting that the interconversion is likely a result of conformational
sampling of the monomer in solution. The Tau monomers exist in solution in a
varying set of structures between the two states, compact and extended. Upon
denaturation, Tau loses this bimodal characteristic and adopts a fully loosened
random coil structure. This result further suggests the two distinct distributions of
Tau structures are a result of solution-phase protein structure.
These experiments are the first to be performed using an ABEL trap to
measure Tau. Additional work in this area to elucidate whether or not the
intramolecular interactions observed in other studies [20], [129] are long lived
(order of seconds) or transient, is planned. These results illustrate that Tau
protein is conformationally heterogeneous in solution. The ability of Tau
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monomers to adopt a variety of transient folds could contribute to its ability to
nucleate and form aggregates in disease.
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Chapter 4 Generating and analyzing different Tau conformations
4.1 Successive seeding cycles result in a change in conformational
ensemble in K18 but not K19
It has been demonstrated that for other amyloidigenic proteins, that
multiple structurally-distinct conformers could be formed in-vitro [56], [130]–[133].
For example, it has been shown that Aβ aggregates formed under either different
conditions can evolve from one conformer to another, over the course of time
[70]. These studies lead us to wonder if it were possible to generate multiple
conformers of Tau in individual samples, and if these conformers were capable of
evolving their structure over multiple cycles of seeding. This was observed and
could suggest that as Tau fibrils spread through the brain, evolutionary pressures
may cause particular structures to propagate in a particular set of conditions.
By stirring Tau monomers and cofactors in solution for several days,
nuclei form and mature into amyloid fibrils. Once a fibril nucleus has formed, it
will mature and elongate the fibril structure through a process called templating
[54]. The formation of the nucleus is the rate-limited step in this process.
To overcome the rate-limiting step in Tau aggregation, fibrils are
preformed over the course of three days under stirring conditions at room
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temperature. Sonicated fibrils are then added to the reaction (#1) containing 25
µM Tau and 50 µM heparin cofactor is incubated at 37 °C for 1 hour. The
sonicated fibrils will serve as a template to accelerate the aggregation of
monomer dramatically (Figure 4.1). The reaction is sonicated on ice and then
used to seed the next reaction (#2), which again contains monomer and cofactor.
This process is repeated until 14 cycles have been completed. At this point the
original seed (3 day stirred material), the 4th cycle, 9th cycle, and 14th cycle are
used to seed 50 µM Tau and 12.5 µM heparin containing reactions (#1, #5, #10,
and #15) for 16 hours at 37 °C for further analysis. The same method of
successive cycles of seeding was applied to K19.

Figure 4.1 Successive seeding cycles scheme. K18 monomers are mixed with a
2-fold molar excess of heparin and allowed to form fibrils for 3 days while stirring.
After sonication, the fibril seeds are mixed with fresh K18 monomers to produce
a new generation of fibrils referred to as cycle 1. The procedure is repeated up to
15 times. In these templated reactions, fibrils are grown quiescently. At distinct
cycles, seeds are removed and used to form an independent set of fibrils for
structural analysis.
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It has been previously shown that after 5 consecutive cycles of Tau
seeding reactions, there is a heterogeneous ensemble of K18 conformers. This
was reported by use of double electron-electron resonance (DEER) spectroscopy
[63]. DEER spectroscopy can be used to measure distances between unpaired
electrons in radicals such as the nitroxide MTSL [58], [63]–[65], [134]. Different
conformations of Tau protein will have subtle differences in their folding, which
results in changes in the distance measured between the two radicals. One
possible explanation for the heterogeneity is that under the conditions provided,
multiple amyloid nuclei can form simultaneously.
After one cycle of seeding, measurements showed the sample to be
homogeneous [64]. Additional cycles of seeding produced an increasingly
heterogeneous ensemble of conformers, which reached an end point at around
10 cycles [64]. The fact that the same protein sequence can form several unique
conformations and faithfully template this structure, suggests that Tau monomer
exhibits a high degree of structural plasticity in solution.

4.2 Analysis of Tau morphology
Fibrils of differing morphologies have been observed in disease [135]–
[137]. In Alzheimer’s disease two distinct fibril types have been noted. Tau fibrils
possess two monomers per layer stacked in the fibril core. These indivually
stacked monomers form a protofilament [71], with two protofilaments associated
in the mature fibril [71]. The morphology of AD fibrils is described as either
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straight filaments (SF) or paired helical filaments (PHF). Straight filaments have
been characterized as flat ribbon-like structures. PHFs are fibrils in which a
helical structure has been observed resulting in a characteristic twisted
appearance. These morphological differences have been reported on by
techniques such as atomic force microscopy (AFM) [138]–[141] and transmission
electron microscopy (TEM) [64], [141]–[143]. Using AFM it was previously shown
that Aβ fibril morphology and structure coevolved over successive cycles of
seeding [144]. Since it was observed using DEER that the structure of Tau fibrils
was evolving over multiple cycles of seeding, a question arose. Were these
structural changes accompanied by changes in morphology? It was observed
that K18 fibril samples from differing cycles did display morphological changes
(Fig 4.2 A – D).
Cycle 1 fibrils were observed to have two or more distinct protofilaments
(Fig 4.2 A). These protofilamets were straight and had a flat striated-ribbon
appearance. These protofilaments were observed to possess variation in the
number of parallel filaments, but most often were observed to have 2-3 lateral
associations. Cycle 10 fibrils were then analyzed for differences with respect to
the Cycle 1 data. Cycle 10 fibrils were characterized by a more heterogeneous
mixture of fibrils, consisting of mostly helical filaments (Fig 4.2 C). These
filaments were observed to have a helical periodicity of 90 -180 nm (n = 50 for
cycle 5 and n = 40 for cycle 10) with a diameter of ~14 nm (n = 100, measured at
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the widest part). Cycle 5 samples were observed to have intermediate
characteristics with both structures being observed to some extent.

Figure 4.2 Evolution of morphology of K18 fibrils by TEM. TEM analysis of K18
fibrils. Cycle 1 fibrils have a distinct striated ribbon appearance (blue arrows) with
varying numbers of parallel filaments (diameter per filament = 7–8 nm),
highlighted in the inset. Fibrils at later cycles are dominated by a typical twisted
appearance (red arrows, diameter ≈ 14 nm, helix periodicity = 90–180 nm). Scale
bars, 100 nm. Panels from left to right represent data for fibrils from cycle 1, cycle
5, cycle 10, and cycle 15, respectively.
The same consecutive cycles of seeding were performed for K19 and the
morphology of these fibrils was also examined using TEM. These experiments
were done less exhaustively because K19 exhibited a high degree of
conformational stability and was not observed to change structure when
subjected to multiple cycles of seeding. K19 fibrils were characteristically ribbonlike and within a sample had differing degrees of lateral associations (Fig 4.3).
The average number of protofilament associations was fairly consistent amongst
differing cycles, however. The individual filaments within the analyzed samples
had average diameters ± SD of 26 ± 13 nm (n = 71), 33 ± 11 nm (n = 69), and 32
± 12 nm (n = 31) for cycles 1, 5, and 10, respectively. The wide distributions and
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similar numbers suggest a variety of, but similar distribution of, parallel filament
arrangements.

Figure 4.3 Conformational stability of K19 fibrils revealed by TEM. Fibrils were
stained with uranyl acetate and analyzed by transmission electron microscopy.
Electron micrographs of fibrils from cycle 1 (A), cycle 5 (B), and cycle 10 (C).
Scale bars, 100 nm. All K19 fibril ensembles measured (cycles 1, 5, and 10)
exhibited similar ribbon-like morphology. Individual protofilaments within these
ensembles have a diameter of 7–8 nm with 3-7 protofilaments per fibril.
4.3 Changes in light scattering and proteolytic sensitivity accompany
conformational changes
Upon ultracentrifugation, the pellets of fibrils from K18 cycle 1 and cycle
10 samples were visually distinct. The pellets of cycle 1 fibrils were white and
tightly packed whereas the fibrils produced after 10 cycles of seeding were
translucent and gelatinous. This implies a changing in the packing of the fibrils
upon centrifugation which could have resulted from a change in fibril structure.
To quantify these observations, a light scattering assay was developed. Turbidity
measurements at 340 nm were taken for cycle 1 through cycle 10 samples for
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K18 and K19. K18 exhibited a decrease in turbidity over successive seeding
cycles (Fig 4.4 A) despite equal amounts of fibrils in solution during each step.
These results suggest a change in the packing of the monomers in the fibrils,
which resulted in a decrease in light scattering.
In order to support the other data which suggested that the structures of
K18 fibrils were changing over multiple cycles of seeding, a proteolysis
experiment was designed. It has been demonstrated in the literature that fibrils of
differing structures have different proteolytic degradation rates [140] ̶ [141]. A
commonly used protease for this is proteinase K (PK). Proteolytic sensitivity
differences are suggestive of changes in the packing of the monomers in fibrils of
unique structures. The changes in monomer packing result in the accessibility of
individual protease cleavage sites within the fibril structure to be more or less
accessible. The differences in accessibilities can result in changes in kinetics of
proteolytic cleavage. To test for this, fibrils formed from an identical concentration
of cycle 1 and cycle 10 samples (Figure 4.4 B, lanes in the gel labeled none)
were proteolytically digested. After addition of protease inhibitor to stop the
reaction, the samples were run on SDS-PAGE to assess the degree to which the
fibrils were digested using PK. It was observed that cycle 10 fibrils consistently
degraded faster (Figure 4.4 B). This is evidenced by the appearance of a lower
molecular weight band in the cycle ten 10 sample upon addition of 7 nM
proteinase K (Fig 4.4 B). With higher concentrations of protease added, a
complete disappearance of the original molecular weight band (undigested K18)
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is observed for cycle 10 but not cycle 1 (Fig 4.4 B) This suggests the cycle 10
fibrils have different protease accessibilities and therefore different rates of
cleavage. A change in the cleavage rate therefore implies a change in structure
has occurred. These results demonstrating the change in dominant structure
were also supported by DEER measurements [147].

46

Figure 4.4 Turbidity and limited proteolysis for K18 samples. A Cycle 1 samples
possessed the highest turbidity and over several cycles turbidity was observed to
decrease. This data is supportive of the fact that conformational changes were
occurring over the course of several cycles and the changes in structural
diversity were completed before the 10th cycle. Turbidity was measured in
Triplicate with SD reported. B Proteinase K (PK) treatment of cycle 1 and cycle
10 fibrils yielded differing digestion products when exposed to protease treatment
for 1 hour. Cycle 1 is less sensitive than cycle 10 is more sensitive to this
treatment. These results support that the two samples contain different
conformational ensembles. (M = molecular weight marker)
Upon ultracentrifugation, the pellets of K19 samples from cycle 1 and 10
both appeared similar. In order to support this quantitatively, light scattering
experiments with K19 cycle 1 and cycle 10 fibrils were performed. No changes in
turbidity were observed over the course of multiple cycles of seeding (Fig 4.5 A).
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To further substantiate that K19 did not undergo structural evolution upon
multiple cycles of seeding, protease sensitivity was measured for cycles 1
through 10. However, no changes in proteolytic cleavage were observed (Fig 4.5
B), implying the structure of the dominant species in the sample is not changing
in these respects, as described for K18. This supports the previous results that
K19 is conformationally stable under these conditions. Proteolysis of K19 cycle 1
and cycle 10 samples was also examined. K19 was more resistant to proteolytic
degradation, which necessitated higher (14 and 140 nM instead of 7 and 70 nM)
proteinase K concentrations. DEER measurements also suggested that the K19
dominant structures were not evolving over multiple cycles of seeding. Taken
together, this data helps to further suggest K19 was not changing dominant
structures over multiple cycles of seeding.
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Figure 4.5 Turbidity and limited proteolysis for K19 samples. A K19 samples
were also measured for turbidity changes with respect to cycle number. No
change in turbidity was observed for K19, supportive of the fact that the
conformational ensembles were not observed to evolve with cycles of seeding.
Turbidity was measured in triplicate with SD reported. B K19 cycles 1 and 10
were also subjected to Proteinase K digestion. Again, supportive of the data
showing no change in structure was occurring, no change in protease sensitivity
was observed for the fibrils.
4.4 Fragility and growth rates drive conformational evolution
It was hypothesized that the change occurs over these cycles is due to a
difference in the fragility of fibrils. A difference in fragility would result in
accelerated growth for fragile fibrils during the period when elongation is
occurring under the initial stirring conditions (220 RPM for 3 days at 22 °C). This
is because the more fragile fibrils will tend to break more often under agitated
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conditions. More broken Tau fibrils lead to more ends, to which Tau can be
recruited. To test this, fibrils were sonicated relatively gently (5% power, in a bath
sonicator (QSonica) for 1 minute). Electron microscopy samples were prepared,
and micrographs were collected. Representative micrographs for each sample
(Figure 4.6 A) show that the fibril lengths are very different for cycle 1 and cycle
10 samples after bath sonication. The micrographs were then quantitatively
analyzed for fibril length using ImageJ. The cycle 1 sample broke to a greater
extent (average = 126 nm, n = 255) than did the cycle 10 sample (average 228
nm, n = 260, Figure 4.6 B).
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Figure 4.6 K18 fibril fragilities determined using TEM. A cycle 1 and cycle 10
fibrils are analyzed by negative stain EM before (upper panels) and after
sonication (lower panels). The fibrils are fractured under mild conditions in a bath
sonicator. Scale bars, 200 nm. When subjected to identical stress, cycle 1 fibrils
are distinctly shorter than cycle 10 fibrils. B, length distributions for sonicated
fibrils from cycle 1 (left panel) and cycle 10 (right panel). The results indicate that
cycle 1 fibrils are more fragile than cycle 10 fibrils.
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This suggests that selection processes may take place during the stirring
step, when fibrils are being initially formed. This selection results in large
enhancement of the fragile population. A mechanism of other fibril population
enhancement was left to be elucidated. It was hypothesized that the other
populations (enhanced in later cycles) grew faster. Quantitative kinetics
experiments could demonstrate this hypothesis. Cycle 1 and cycle 10 needed to
be sonicated until they were equal size. This would allow for equimolar amounts
of fibrils (and therefore ends) to be added in seeded kinetics experiments, in
order to evaluate the growth rates of cycle 1 and cycle 10 samples. To test this,
the cycle 1 and cycle 10 samples were subjected to 2 minutes of sonication on
ice with a tip sonicator set to 20% power. Electron micrographs were collected,
and fibril lengths were assessed after tip sonication. The lengths of fibril seeds
were quantified using ImageJ. Representative micrographs with the resulting
length distributions from the fibril samples are shown (Fig 4.7 A – D).
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Figure 4.7 Quantified Tau fibril breakage under harsh sonication conditions.
Negative stain EM images of cycle 1 (A) and cycle 10 (B) fibrils subjected to
harsh sonication conditions with the sonicator tip immersed in the fibril solution.
Scale bars, 200 nm. Length distributions of cycle 1 (C) and cycle 10 (D) fibrils.
The lengths of 526 fibrils from cycle 1 and 493 fibrils from cycle 10 were
measured. The average lengths of cycle 1 and cycle 10 fibrils were 64.2 nm and
60.4 nm, respectively.
Since it was possible to generate nearly identical sizes of preformed fibrils
with different conformations, it became possible to quantitatively analyze the
samples for seeded kinetic growth rates. To test whether or not the differences in
growth rate for cycle 1 and cycle 10 samples were contributing to conformational
heterogeneity, thioflavin T kinetics were performed. Thioflavin T is an amyloid
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specific dye that binds to β-sheets [142] ̶ [143]. Upon binding the fluorescence
emission spectra red shifts and increases in emission intensity [150]–[152].
Monitoring the increase in fluorescence emission intensity of thioflavin T versus
time allows for the rates of growth to be monitored. Fibril concentrations were
quantified (using the BCA assay) after sonication and therefore the same amount
of fibril could be added to each reaction. It was shown that the kinetics of seeded
growth were different for cycle 1 and cycle 10 fibril samples (Fig 4.8). Cycle 10
samples (Fig 4.8, red trace) reached completion 2 times faster than the cycle 1
(Fig 4.8, blue trace). The t50 was 17 and 8 minutes for cycle 1 and cycle 10,
respectively. The results of these experiments were reproduced in triplicates,
from independent batches of seeds, which ensured reproducibility and rigor. This
data allows for a more complete understanding of the mechanism of selection
taking place in the multicycle seeding experiment with K18. Since K19 was not
observed to change structure over successive seeding cycles, this analysis of
breakage and kinetics was not performed.
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Figure 4.8 Differences in growth rates of K18 conformations. 2% seeds
(monomer equivalents) were mixed with 25 μM K18 monomers and 50
μM heparin. Fibril growth of cycle 1 fibrils (blue trace) and cycle 10 fibrils (red
trace) was monitored by thioflavin T fluorescence. All values represent average ±
SEM (n = 6 replicates).
4.5 3R Tau cannot grow on cycle 1 or cycle 10 material
It has been previously demonstrated that Tau fibrils composed of the
MTBRs of 4R Tau cannot recruit 3R Tau. This results in an asymmetric seeding
barrier [57], [63], [130]. This phenomenon was first observed using material that
was stirred for three days to generate Tau fibrils. Using ultracentrifugation and
SDS-PAGE it is possible to separately analyze Tau protein found in the pellet
(fibril) or in the supernatant after a seeded reaction. These experiments allow for
the examination of whether or not K19 (3R Tau) was being recruited onto the
K18 (4R Tau) fibril. Would the cycle 10 conformational ensemble be able to
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recruit and template K19? When seeds generated from cycle 1 and cycle 10
were added to K18, both samples fully recruited the K18 monomers (Fig 4.9 A).
This demonstrates the seeding competency of the fibrils added to the reaction.
Despite their ability to recruit K18, the cycle 1 and cycle 10 samples were not
shown to incorporate K19 to an appreciable degree (Fig 4.9). These results
suggest the seeding barrier previously observed is robust and does not become
diminished after the conformational change (of the K18 seed) produced here
(Figure 4.9).

Figure 4.9 Examination of Tau seeding barrier for distinct conformations. 5%
seeds (monomer equivalents) from cycle 1 and cycle 10 fibrils were mixed with
25 μM K18 or K19 monomers and 50 μM heparin. Fibrils were allowed to grow
for 24 h at 37 °C. Equivalent amounts of pellets (P) and supernatants (S) were
analyzed by SDS-PAGE and Coomassie Blue staining. Whereas K18 monomers
grow onto K18 seeds (A), K19 monomers do not (B). The arrow in B refers to
K18 protein bands that originate from the seeds. The data highlight that both
populations of K18 fibril conformers are unable to recruit K19 monomers.
4.6 Fragility and growth rates govern fibril selection
One possible explanation as to why fragile fibrils are enriched in mild
stirring conditions could be that if certain populations are more fragile, they will
break more often than their less fragile counterparts. Since the end of the fibril is
the site of new amyloidogenic growth, the fragile fibrils which generate more
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ends, therefore exhibit more growth in these conditions. Long fibrils do not
elongate efficiently [153], [154]. Over several days, the dominant species in
solution becomes the one which will break the most under the given conditions.
Under tip sonication, both fibril species break similarly. This means whichever
grows faster in quiescent conditions will evolve as the dominant species through
several cycles of templating new monomer onto fibrils from the previous reaction.
Over repetitive cycles of fracture and growth this conformer will become
the dominant species (upper reaction path) (Fig 4.10). Inefficient breakage
selectively fractures the more fragile conformer (L-shape) (Fig 4.10). If repeated
over multiple cycles (continuous stirring) this conformer will become the dominant
species (lower reaction path). Note that the depicted conformers are only
models. The real structures of Tau fibrils will be more complex and include
additional β-sheets. The number of cycles required for evolving a dominant
species will depend on the structural composition of the original ensemble and
the specific parameters of fracture and growth. In cases where the fragilities and
growth rates of different conformers are similar, the populations may have
multiple dominant fibril species. It is conceivable that within neuronal cells,
molecular chaperones or other machineries could facilitate the breakage of fibrils
and influence growth.
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Figure 4.10 Conformational selection based on fracture and growth. In a
heterogeneous mixture of Tau fibril conformers, depicted as stacks of β-stranded
segments (green arrows) in U- and L-shape conformations, efficient breakage
(intense sonication) results in seeds with identical extensions along the fibril axis.
Under these conditions the number of fibril ends that can recruit soluble
monomers is the same for the different conformers giving the faster growing seed
(U-shape) a selective advantage.
It was shown that K18 fibrils can form multiple nuclei under stirring
conditions in-vitro. Upon changes in the growth conditions, selection processes
can evolve the dominant population. Other possible explanations for the change
in dominant fibril species do exist, however. Such explanations include
secondary nucleation [155]–[157] and strain switching [50], [144], [158]. These
results demonstrate a model for how breakage and growth rates may play an
important role in disease, and how this process could allow certain populations to
become enriched in particular brain regions. Biophysical properties of amyloid
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fibrils could drive pathology and subsequently enable the phenotypic diversity
found in Tauopathies [159].
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Chapter 5 Stability of Tau fibrils
5.1 Limited dilution of Tau fibrils does not cause dissociation
Thermodynamic stability is an important aspect to study when trying to
understand protein aggregates. Tau protein is very electropositive at neutral pH.
The positive charges in Tau are what allows Tau to perform its native functions of
binding to and stabilizing negatively charged microtubules. To induce Tau
aggregation in-vitro, a polyanionic cofactor must be added to compensate for the
many positive charges in Tau. This cofactor has been shown to bind to the Tau
monomer [160], change its conformation [129], and stabilize the fibril [57].
Therefore, it follows that understanding the interaction between the cofactor and
the Tau fibril is critical to our understanding how these aggregates form.
It has been suggested in the literature that cofactor molecules may be only
required for the initial steps of nucleation [160]. However, it has also been
demonstrated that without addition of cofactor, seeded templating of Tau was not
observed [57]. Additionally, utilizing a fluorescence anisotropy experiment, it was
observed that it was possible to exchange cofactors, which demonstrates the
surface accessibility of cofactors. It was observed that not all of the cofactors
associated with Tau filaments could become displaced, however [57]. Molecular
exchange can only occur with cofactors decorating the outside of the fibril. Some
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of the cofactor may be inaccessible to the solvent which suggests some of the
cofactors associated with Tau fibrils may be buried in the interior of the fibril core.
In order to test whether the cofactor mediated fibril stabilization was driven
by thermodynamic equilibrium, fibril dilution experiments were performed. The
experiments below were performed by diluting preformed fibrils in the presence
or absence of cofactor, and sedimenting the fibrils after 12 hours of incubation at
37 °C. These results demonstrate that with limited dilution, regardless of whether
RNA cofactor was included in the dilution, the fibrils do not dissociate (Figure 5.1,
top and bottom).

Figure 5.1 Limited dilution of Tau fibrils. Upon dilution in the presence or absence
of cofactor, K19 and K18 fibrils were not observed to dissociate. This result
suggests that once formed, Tau fibrils are stable and resistant to concentrationdependent depolymerization.
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These results are important because they highlight the stability of Tau
fibrils, even in the absence of cofactors. Stability is essential for fibrils during cellto-cell transmission, for example.
5.2 Adding high salt does not dissociate RNA cofactors or Tau fibrils
It was observed that it is possible to inhibit growth of seeded Tau reactions
by addition of either 0.5 M or 1.0 M NaCl, depending on the cofactor used [57].
This effect is likely in part due to the increased competition between the
polyanionic cofactors (polyRNA or heparin sulfate) and the salt for the positively
charged fibril surface. Additionally, it is likely that increased salt concentration
could enhance the hydrophobic interaction between monomers in the fibril. This
would therefore disfavor fibril dissociation. It is not clear what the contribution of
these two effects to fibril elongation are at this time. To understand if cofactors
bound to the fibril surface are capable of becoming displaced by salt, fibrils
formed with RNA at 100 mM NaCl were adjusted to 500 mM NaCl, incubated for
10 minutes at 37 °C, and sedimented via centrifugation. RNA bound to fibrils was
co-sedimented into the insoluble pellets fraction (which contained Tau fibrils and
associated RNA). The pellets were taken up in 2% SDS and subsequently
adjusted to 1250 µL with assembly buffer. RNA concentration was then
quantified in samples using the absorbance at 260 nm (using the following
equation: A260 nm = 1 = 40 µg/mL). It was shown that the cofactor/fibril interaction
was not diminished significantly by the increase in the salt concentration (Figure
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5.2 A). These results are important because they suggest the cofactor/fibril
interactions are strong and specific.
It could be possible for fibrils to dissociate upon addition of high salt,
despite maintaining a majority of the ionic interactions with cofactors. To test this,
fibrils previously formed with RNA and adjusted to 500 mM NaCl for 15 minutes
were sedimented, and protein content was compared using SDS PAGE. It was
also shown that upon addition of high salt concentrations, the sedimentable
material was unchanged (Fig 5.2 B). This result suggests that once the fibrils are
formed, that the various interactions between monomers in the fibril are sufficient
to disfavor dissociation under these conditions. Although 500 mM salt
concentrations are not found in-vivo these results are important contributions to
understanding the stability of Tau fibrils and their associated cofactors.
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Figure 5.2 Addition of high salt does not dissociate cofactors or monomers. A
Normalized intensity of RNA UV280 nm absorbance for K18 and K19. Fibrils
were formed at 100 mM NaCl and upon addition of 500 mM NaCl, the RNA
cofactor was observed to marginally dissociate (~20% for K18 and 10% for K19).
B Identical samples were ultracentrifuged (130,000 x g) and pellets were taken
up in 1X Laemmli Sample Buffer and analyzed by 15% SDS PAGE. The results
indicate that fibrils do not dissociate upon addition of high salt.
There are alternative explanations that would explain why the higher salt
concentrations were unable to dissociate cofactors. For example, any cofactors
buried in the fibril’s interior would not likely be dissociated from fibrils. These
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buried cofactors would be unable to be exchanged and also could contribute to
the stability observed for the fibrils in the limited dilution experiments.
Cofactor molecules have been shown to be associated with NFT in-vivo.
Gaining a deeper understanding of how fibrils associate with cofactors will likely
contribute to our understanding of the pathology involving Tau fibrils. For
example, it has been shown that sulfonated polysaccharides (such as heparin)
are found conjugated to some extracellular membrane proteins, and these can
help mediate internalization and transmission of fibrils [161]
These results are important because they suggest that Tau fibrils are
stably folded. This is relevant for seeding assays, which rely on fibril stability.
Fibrils cannot spontaneously dissociate or fibril seeding experiments would not
be possible. This is because as a small amount of seeds are added to a reaction
there is a large dilution. If Tau fibrils spontaneously dissociated upon dilution they
would be incapable of acting as seeds and would not template new Tau
monomer.
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Chapter 6 MAP2 Binds to the end of Tau fibrils; Preventing Seeded
Aggregation and slows nucleation-Based aggregation
6.1 Sequence similarity between MTBRs of Tau and MAP2
Microtubule associated proteins have been shown to perform similar
functions in healthy cells. These functions include binding to and stabilizing or
crosslinking the microtubules in neurons [162]–[164]. The semiconserved
functions of MAP2 and Tau are due to the high sequence identity in the
microtubule binding repeat regions (Fig 6.1).

Figure 6.1 Comparison of MAP sequences in MTBRs. MTBRs for 3R (K19) and
4R (K18) Tau and MAP2. Native cysteines are marked by a blue star and red
residue letter. Identical regions are boxed in red.
These proteins serve similar functions as monomers in the cell and bind to
microtubules through a similar sequence called microtubule binding repeat
regions [165]–[167]. NFTs are comprised mainly of phosphorylated Tau [4].
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MAP2 epitopes have been shown not to be present as a major component of
NFTs. However, this does not exclude small amounts of MAP2 from being
present in the mature NFT [188] ̶ [189].
Tau fibrils grow by recruiting monomeric Tau onto their ends. The Tau
monomer adopts the structure of the fibril template and extends the fibril. The
consequence of this is that identical residues of adjacent monomers, along the
fibril axis are stacked on top of one another. The result of this is an elongation of
the fibril along the long fibril axis [54], [130]. The templating process can result in
different conformations of Tau fibrils being formed (as in Chapter 4). Previously, it
was shown that a single point mutation can result in a selection of seed
conformation [58]. An extreme case of sequence driven selection occurs with 3R
Tau, which will not recruit onto the 4R fibril end. This results in an asymmetric
seeding barrier [130]. These incompatibilities with growth might occur due to
inability of monomers to adopt different conformations. The incompatibility could
be due to subtle or extreme differences in sequence between the species.
Considering that the fibrils are comprised of the MTBRs and that these regions in
MAP2 and MAPT are highly homologous, it was hypothesized that MAP2 could
bind to the end of the Tau fibril, cap it, and thereby inhibiting the recruitment of
Tau monomers (Figure 6.2).
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Figure 6.2 Hypothetical model of MAP2 binding to the end of Tau fibrils. A In the
absence of MAP2, the Tau protein is capable of continuing the structure until the
monomer or heparin is depleted. The structure of Tau fibrils is templated faithfully
and the notches in the diagram represent this continuation of structure. B In the
case where MAP2 has been added, the Tau fibrils are capable of recruiting one
MAP2 molecule, on the end of the fibril, as it possesses the correct structural
plasticity to adopt the conformation presented by the Tau fibril. Subsequent
layers are incapable of incorporating due to some constraint on the Tau and
MAP2 monomer that inhibits its ability to elongate the fibril beyond the initial
deposition of a layer.
6.2 Inhibition of seeded Tau fibril elongation
To test whether or not MAP2 could inhibit Tau growth, K18 seeds were
added to monomer and heparin to allow for growth that could be monitored by
thioflavin T (ThT) fluorescence kinetics (as previously described in Chapter 4.6).
The K18 in the absence of MAP2 efficiently aggregated and the aggregation was
completed in 4 hours (Figure 6.3). By including either 3R or 4R MAP2 MTBR
isoforms in seeded Tau experiments, a consistent and powerful blocking effect
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was observed. This effect was demonstrated by sub stoichiometric
concentrations of MAP2 (2.5 µM) with respect to Tau monomer (10 µM). It was
shown that 3R MAP2 reduced ThT signal by 65% and 4R by 90% (Figure 6.3 A).
These effects were measured in quadruplicate and plotted with SEM values.
Fibril growth can also be monitored by sedimenting the insoluble material by
ultracentrifugation after the reaction is complete. This fractionates fibrillar and
monomeric Tau. By dissolving the pellets (insoluble fraction) in the same volume
of 1 x Laemmli sample buffer as the original reaction, pellets can be directly
compared to supernatants by SDS PAGE. It was shown that addition of
substoichiometric concentrations of MAP2 MTBRs to the K18 seeded reaction,
resulted in a dose-dependent blockage effect (Figure 6.3 B - D). The
reproducibility of these experiments was demonstrated by use of three
independent batches of seeds (biological triplicates) which were quantified by gel
band densitometry using ImageJ. The resultant quantifications were analyzed in
GraphPad using a one-way ANOVA test. The 3R MAP2 resulted in 60%-75%
reduction (p < 0.0001) in K18 aggregation (Fig 6.3 B and C). 4R MAP2 was
slightly more potent and resulted in 65-80% (p < 0.0001) reduction in K18
aggregate formation (Figure 6.3 B and D). It was noticed that the MAP2 protein
consistently ends up in the pellet fraction of these experiments (Fig 6.3 C -D,
bands in pellet (P) lane below the K18 (3R MAP2) and above the K18 (4R
MAP2). This would suggest that MAP2 is aggregating under the quiescent
reaction conditions. However, the reduction in ThT signal (Figure 6.3 A) would
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suggest the MAP2 is not forming fibrillar material in place of Tau. This is because
the ThT assay measures the relative amount of β-sheet character of proteins in
solution (and therefore the relative monomer to fibril conversion). MAP2 is not
appreciably contributing to the ThT signal however (Fig 6.3 A). If it were,
blockage would be obfuscated by the increase in fluorescence by MAP2. These
results suggest that the MAP2 protein might be either binding to Tau aggregates
(but not being incorporated into the fibril structure), or they might be forming nonamyloidogenic aggregates, or both.
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Figure 6.3 3R and 4R MTBRs of MAP2 block K18 growth in seeded reactions. A
Thioflavin T kinetics of K18 growth in the absence or presence of 3R or 4R MAP2
MTBRs. B One-way ANOVA analysis of MAP2 blockage in 3 sedimentation
experiments (biological replicates). p < 0.0001 from one-way ANOVA for each of
the different concentrations of MAP2 when compared to –MAP2 reactions. Band
intensity was calculated by IP/(IP+IS), where IP and IS are the integrated band
intensities measured in ImageJ from SDS PAGE gels for the pellet (IP) and
supernatants (IS). C and D Representative SDS PAGE gels of 3R and 4R MAP2
blocking K18 growth, respectively.
6.3 Inhibition of K18 nucleation by MAP2 MTBRs
Nucleation dependent kinetics can be monitored via ThT also. Once the
nuclei form, they begin to elongate and consume monomer via the templating
mechanism. This results in an initial lag phase in which the fluorescence
emission intensity of ThT in solution is low. Once the nuclei have formed and
begin to grow, the ThT binds and the emission intensity in solution increases.

71

Eventually, the monomer is fully incorporated in the fibril structure and the
increase in ThT signal plateaus.
The MAP2 blockage effect was so potent for a seeded reaction, it was
hypothesized the MAP2 MTBRs may slow or inhibit nucleation dependent
kinetics experiments also. It was shown that in the absence of MAP2 K18
aggregated fully within 5 hours (Figure 6.4). By the addition of 3.2 µM MAP2
MTBRs, a large increase in the time for K18 (25 µM) to aggregate in these
reactions was observed (Fig 6.4). The K18 protein in the absence of MAP2,
aggregates fully, and has a T50 of 2.5 hours. By inclusion of MAP2 protein, the
nucleation of Tau slowed to have a T50 of 5.5 hours (Fig 6.4). This represents a
doubling of the time required to nucleate. The overall signal intensity was also
reduced indicating that it is not only slowed by this but the total amount of ThT
positive Tau aggregates were reduced by as much as 20% (Fig 6.4). The
reduction in ThT positive aggregates again suggests that MAP2 is not being
incorporated into the fibril but is inhibiting the Tau protein from fully aggregating.
The fact that the overall reduction in Tau aggregation is less potent than
for a seeded experiment can be explained. In a nucleation experiment, K18
monomers in the 96 well plate are shaken in order to induce aggregation. This
shaking could break already formed fibrils, thereby negating the effect of MAP2
blockage by exposing new ends to which K18 can grow. If MAP2 were templating
onto the fibril, one would expect the signal for a + MAP2 experiment to be higher
than for that of the K18 only samples.
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Figure 6.4 MAP2 3R and 4R can slow nucleation of K18 in-vitro. Tau protein and
heparin cofactor incubated under shaking conditions nucleates with a T50 of 3
hours (red). MAP2 3R and 4R both slow the aggregation rate of Tau to T 50 of 5.5
hours (green and blue respectively).
6.4 K19 does not block K18 aggregation
K19 also has high sequence similarity to K18. It has been shown that K19
is incapable of growing on K18 (Chapter 4, Figure 4.9). However, it had not been
examined whether K19 could interfere with K18 aggregation. In the previous
blockage experiments, MAP2 monomers were added at 5.0 µM final
concentration. This concentration achieved the maximum decrease in K18
aggregation. It was shown that in a seeded reaction in the absence of K19, K18
fully aggregated (Fig 6.5). To a separate K18 seeded reaction, 5.0 µM K19 was
added. It was shown that K19 was not capable of blocking K18 aggregation (Fig
6.5). This result is important because it demonstrates that the inhibition of Tau is
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caused by MAP2 sequence dissimilarity not the fact that its highly homologous. If
homology were the only factor to consider, the K19 should have caused an
obvious decrease in K18 aggregation since K19 shares 75% sequence identity
with K18. Instead, this result suggests that the ability for MAP2 to block Tau
aggregation is likely caused by the sequence dissimilarity between Tau and
MAP2.

Figure 6.5 K19 does not block K18 aggregation. SDS PAGE of K18 reactions
demonstrate that K18 fully aggregates and K19 does not inhibit K18 aggregation
appreciably. Upon ultracentrifugation, K18 is in the pellet (P) in both cases. K19
remains soluble and does not grow on K18. P = pellet, S = supernatant
6.5 Heparin sequestration does not account for blockage
It was noticed that when MAP2 and heparin were combined, rapid
aggregation of the MAP2 would occur, resulting in a cloudy solution. This
occurred even in the absence of seeds. It was observed that if these solutions
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are pelleted in the ultracentrifuge and the resultant pellets are analyzed by SDS
PAGE, the white precipitate is MAP2. The MAP2 protein would consistently also
become insoluble in the sedimentation experiments shown previously, but it was
not appreciably increasing the ThT signal in either the seeded or nucleation
experiments. These results together suggest that unlike Tau, MAP2 is forming
aggregates in the presence of heparin which are not amyloidogenic. To examine
the morphology of these aggregates K18, 3R MAP2, or 4R MAP2 were incubated
with heparin and K18 seeds for 6 hours at 37 °C (identical to the seeded
experiments shown in Chapter 6.2). MAP2 proteins produced white pellets, which
resembled those of K18 monomer with seed. When these samples were
prepared for TEM analysis, the morphology of the aggregates became evident.
K18 produced long fibrils as expected (Fig 6.6 A). MAP2 containing samples
were demonstrated to contain large amorphous aggregates rather than fibrils (Fig
6.6 B and C). This result suggested that although MAP2 is capable of interacting
with heparin – it seems to preferentially form amorphous aggregates instead of
fibrils.
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Figure 6.6 TEM of K18 and MAP2 aggregates. A Representative negatively
stained electron micrograph of K18 WT fibrils formed after incubation overnight
with heparin, cofactor, and seeds. B and C Representative micrograph of
amorphous aggregates formed from 3R and 4R MAP2 monomers incubated
overnight with heparin cofactor and seeds, respectively.
Since it was observed that MAP2 could block Tau aggregation but also
simultaneously aggregated with itself in the presence of heparin, the following
question arose. Would it be possible to rescue the Tau fibrilization by additional
heparin in the seeded experiments? To test this, experiments with identical
conditions to the previous blockage experiments were performed. In addition,
reactions in which the heparin concentration was doubled and quadrupled were
performed in parallel. The previous experiments in which seeded Tau
aggregation was blocked by MAP2 contain 20 µM heparin. This is a four-fold
higher concentration than the MAP2 present (5 µM). In the next experiment, the
heparin was doubled (40 µM, 8 x higher than MAP) and quadruped (80 µM, 16 x
higher than MAP2) in order to determine if more aggregation of Tau would be
observed. No increase in the aggregation of Tau upon addition of more heparin
was observed for either 3R (Fig 6.7 A and C) or 4R MAP2 (Fig 6.7 B and D).
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Heparin titration experiments were performed using three independent batches of
K18 seeds (biological triplicates), and the resultant fibrils were ultracentrifuged as
before. Pellets were dissolved in 1 x Laemmli sample buffer equal to that of the
supernatant. The pellets and supernatants were analyzed on SDS PAGE and the
protein bands in the gels were quantified using ImageJ. Band intensity found
using gel densitometry was plotted in GraphPad. A one-way ANOVA test was
performed to find p-values. The blockage in seeded experiments with 20, 40, or
80 µM heparin by 5 µM of both MAP2 isoforms is very similar (Fig 6.7) to that of
the blockage observed in the regular heparin (20 µM) regime (Fig 6.3). This
result suggests that sequestration of heparin by spontaneous MAP2 aggregation
is not likely responsible for the blockage effect observed for K18 seeded
reactions.
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Figure 6.7 Heparin titration does not rescue Tau aggregation. A and B
Representative gels of 3R and 4R MAP2 heparin titration experiments,
respectively. C and D One-way ANOVA analysis of ImageJ densitometry of
heparin titration gels. Experiments were performed in triplicate (biological
replicate). From one-way ANOVA, P < 0.0001 for each + MAP2 reaction
compared to corresponding – MAP2 reaction. P = pellet, S = supernatant
6.6 K18 inhibition by MAP2 is not caused by large aggregates of MAP2
Through these experiments it became evident that MAP2 was not blocking
the aggregation of Tau protein by way of binding the cofactor. It was not clear,
however, if the aggregates of MAP2 themselves were somehow responsible for
the blockage effect observed. So next, MAP2 was incubated in either the
presence or absence of heparin for 16 hours at 37 °C. This material was
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subsequently used in a K18 blockage experiment as before. K18 monomer and
heparin was seeded. Blockage experiments including the MAP2 incubated with
or without heparin were performed in parallel. Insoluble protein was sedimented
and pellets were compared to supernatants using SDS PAGE. It was shown that
if MAP2 is aggregated (Fig 6.8 the lanes labeled Agg) prior to being used as a
blocking agent, the blockage effect is abolished nearly completely for both
isoforms 3R and 4R, respectively (Figure 6.8 A – B). However, if MAP2 (3R or
4R) was incubated without heparin in assembly buffer, then blockage was
observed. This result would suggest the large amorphous aggregates observed
under TEM are not responsible for the blockage of K18 seeded reactions.

Figure 6.8 Aggregated vs monomeric MAP2 blocking Tau aggregation. K18 WT
and heparin with 10% seeds incubated for 6 hours grows fully (- = K18 seeded in
the absence of MAP2). Inclusion of 3R (A) or 4R (B) MAP2 incubated with
heparin overnight does not result in blockage when subsequently added to a K18
seeded reaction (Agg = aggregated). However, if MAP2 was instead incubated in
the absence of heparin overnight, blockage of Tau aggregation is observed for
both 3R and 4R MAP2 (Mon = monomeric). P = pellet, S = Supernatant
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These results taken together suggest that MAP2 can form aggregates
under quiescent conditions, but these aggregates are not amyloids. Additionally,
the blockage effect is quite potent when monomeric MAP2 is used but completely
abolished with aggregated MAP2. This would suggest that monomeric MAP2 or
small aggregates are blocking the Tau from elongating. It was still unclear at this
point whether the MAP2 was interacting directly with the fibril or causing any
elongation of the fibrils.
6.7 MAP2 does not elongate Tau fibrils
To understand if the MAP2 was interacting with the fibril, it first needed to
be established whether or not the K18 fibrils were elongating in the presence of
only MAP2 monomer.
The next set of experiments were devised using TEM in order to
understand whether or not truncated MAP2 3R and 4R isoforms could be
recruited and extend Tau fibrils in-vitro. If the MAP2 monomers are extending the
fibril length, it should be observable under TEM. K18 seeds were incubated at
the same concentration, in the absence of additional monomers. This was
important to set a baseline size for the seeds and would also ensure fibril
dissociation wasn’t skewing the analysis. TEM samples of the seeds added to
K18 monomer served as a positive control, to ensure the seeds are truly
competent to induce aggregation. Samples of K18 seeds with MAP2 monomers
added were then compared using TEM.
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Samples of K18 seeds incubated with only buffer had an average size of
108 nm (Figure 6.9 A), and representative micrographs are depicted (Fig 6.9 B).
K18 fibrils were shown to increase to an average length of 326 nm (Fig 6.9 C)
when incubated with K18 monomer. Fibrils were clearly longer in these samples
(Fig 6.9 D). When either 3R or 4R MAP2 monomer was added in the experiment,
instead of Tau, K18 fibrils were not observed to increase in size. These fibril
samples were observed to be 108 and 106 nm long in the presence of MAP2 3R
and 4R respectively (Fig 6.9 E and G). The micrographs of samples containing
MAP2 monomers looked indistinguishable from the buffer control samples
(compare Fig 6.9 B with F and H). These results indicate that MAP2 is unable to
significantly extend the fibrils. This is consistent with the observations that MAP2
is not considered a major component of Tau fibrils or NFTs in the brain[4] and
that the ThT signal of K18 seeds did not increase in the presence of MAP2
monomers.
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Figure 6.9 Fibril length analysis of MAP monomers with seeds. A Quantification
of fibril length measurements for K18 seed only sample. B Representative
micrograph of K18 seed used in this experiment. C Quantification of K18 fibril
length after seeds were incubated with 10 µM monomer and 20 µM heparin for 6
hours at 37 °C. D Representative EM of K18 fibrils measured. E and G
Quantification of K18 fibril length after seeds were incubated with 3R or 4R
MAP2 respectively. F and H Representative EMs of seeds incubated with MAP2
3R or 4R for six hours respectively. Scale bar is 100 nm.
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6.8 MAP2 binds to Tau fibrils
The previous results exclude large aggregates as being responsible for
the MAP2s blocking effect observed. Additionally, the MTBRs of MAP2 isoforms
were not observed to elongate Tau fibrils appreciably. Still, it needed to be
established if MAP2 was physically binding to the Tau fibril. If Tau aggregation is
being blocked by MAP2 interacting with the end of the fibril, it could be possible
for the effect to be caused by only a single to a few layers of MAP2. This would
not be sufficient increase in length to be observed using TEM. Binding of
monomers to fibrils can be observed using fluorescence anisotropy. This is
because as monomers bind to the relatively massive fibril, the tumbling of labeled
protein in solution will slow. Decreased protein tumbling would reduce the rate of
emission dipole depolarization and therefore increase anisotropy (according to
equation in section 2.19). To test whether MAP2 was binding to the fibril, a single
mutant for 4R MAP2 was generated by removal of the native cysteine found in
the 2nd repeat (C409S). The natural cysteine in the 3rd repeat exists in both 3R
and 4R MAPs. Both 3R and 4R isoforms of MAP2 and Tau were labeled with
Atto 647N maleimide. Initially, anisotropic measurements vs time were taken to
establish a rate of binding. When 100 nM of labeled MAP2 isoforms were mixed
with 10 µM sonicated Tau fibrils, the labeled proteins were observed to have
rapid binding kinetics and the reactions were complete well before the 15-minute
collection time (data not shown).
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Establishing a binding assay using fluorescence anisotropy would allow
for examination of kinetics for MAP2 and K18 seeds. Fluorescence anisotropic
increases were observed for K18, 3R MAP2, and 4R MAP2 (Fig 6.10 A – C).
Experiments were performed using three independent batches of seeds
(biological replicates) and averaged with SEM shown. K18 was used as a
positive control and the K19 as a negative control. If the MAP2 is binding to the
end of the fibril, an increase in fluorescence anisotropy for the MAP2 proteins
and K18 should be observed. Since K19 is incapable of templating on K18, due
to the asymmetric seeding barrier, the anisotropy for K19 should not change. The
average maximum anisotropic value for experiments containing MAP2 were
found to be 0.35 and 0.36 for 3R and 4R, respectively (Figure 6.10 A - B). These
curves were plotted in GraphPad and apparent KD were found to be 2.8 µM and
1.6 µM for 3R and 4R MAP2, respectively. The maximum change in anisotropy
for labeled K18 incubated with seeds was observed to be an average of 0.26 with
an apparent KD of 3.9 µM (Figure 6.10 C). The apparent KD for MAP2 being
lower than for Tau could explain how the blocking effect may take place, in-vitro.
The MAP2 can bind to the fibril more tightly than a Tau monomer would. This is
indicative of strong binding to the fibril. The seeds used in these experiments
were formed in the presence of heparin to induce aggregation. It is possible that
some heparin in these reactions was not bound to the fibril. Unbound heparin
could cause aggregation of MAP2, which could result in artifactually high
anisotropy values. The seeds for these experiments were made with an 8 to 1
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ratio of Tau to Heparin. This means that with 20 µM of K18 seeds added, and if
all of the heparin in solution was not bound to the fibrils, 2.5 µM of free heparin
would be have been added to the monomers in the anisotropy experiments. In
order to test the degree to which this effected the change in anisotropy 2.5 µM of
heparin was added to 3R and 4R MAP2 monomers. Very little to no change was
observed for the anisotropy of the MAP2 proteins as compared to only buffer
added (data not shown). These results demonstrate that the labeled MAP2 and
K18 proteins are binding to the fibril and not to heparin or the cuvette. For K19,
as expected, no change in anisotropy was observed for even the highest
concentration of K18 seed (Fig 6.10 D).
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Figure 6.10 Fluorescence anisotropy changes induced in monomers by titration
of seed. 100 nM 3R (A) or 4R (B) MAP2 were titrated with 0.310 - 20 µM K18
seeds. The seeds produce large changes in anisotropy for the monomers with KD
values at 2.8 µM and 1.6 µM, respectively. C K18 seeds induce anisotropic
changes for K18 also with an apparent KD of 3.9 µM. D K19 was used as a control
since it does not template on K18, even at high seed concentrations. Experiments were
performed using three independent batches of K18 seeds. Results are averaged, and
SD reported. Curve fitting and KD analysis was performed in GraphPad.

6.9 MAP2 captures Tau fibrils from solution
The fluorescence anisotropy experiment was indirect evidence of MAP2
binding to Tau fibrils. To support this further a bead-capture experiment was
performed. In this experiment commercially-available magnetic beads conjugated
to streptavidin (NEB) were purchased. Biotinylation of Tau and MAP2 monomers
would allow for these biotinylated monomers to bind to the magnetic beads. By
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placing the magnetic bead slurry in a magnetic field, the beads (which are
attached to the monomers) can be pulled from solution and washed. If K18 seeds
can bind to MAP2 monomers, then these magnetic beads with biotinylated
monomers should be capable of capturing the fibril seeds from solution. If the
monomers are binding to the fibril, then the beads should be capable of isolating
fibrils attached to the biotinylated monomers by way of interaction with the
streptavidin conjugated to the magnetic beads. The biotin-streptavidin bond can
be disassociated by boiling the beads in 1 X SDS (Laemmli) sample buffer.
Utilizing a PEG11-Biotin maleimide labeling reagent (Thermo Fisher), the
monomers (K18, K19, 3R MAP2, and 4R MAP2) were labeled utilizing a single
cysteine at the N-terminus of each protein. PEGylation is a useful characteristic
of this label and is used in order to provide enough of a spacer such that the
biotin molecule attached to the proteins can still interact as a ligand to
streptavidin.
K18, 3R MAP2, 4R MAP2, and K19, conjugated to biotin, bind to
streptavidin coated magnetic beads (faint bands above arrow for K18 and 4R, or
below the arrow for 3R and K19, Fig 6.11). K18, 3R MAP2, and 4R MAP2 are
capable of binding to K18 seeds (Fig 6.11, the large band indicated with an
arrow). K19 and hydrolyzed biotin label were each incapable of binding to K18
(Fig 6.11). This result is important because it shows that the K18 and both 3R
and 4R MAP2 tightly bind to seeds and are released upon boiling of beads in 1X
Laemmli sample buffer. This experiment reconfirms the result that K19 does not
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interact with K18 fibrils, which is the basis for the asymmetric seeding barrier.
Also beads and hydrolyzed biotin label alone are insufficient to pull Tau seeds
from solution.

Figure 6.11 Streptavidin conjugated magnetic beads pull seeds out of solution by
way of biotinylated monomers. Biotinylation at the N-terminus of K18, 3R MAP2,
4R MAP2 resulted in an ability to bind to beads and K18 seeds. The bound
seeds are eluted with biotinylated monomers during boiling in 1 X Laemmli
sample buffer. Biotinylated K19 and hydrolyzed PEGBiotin reagent did not
however demonstrate the ability to bind to seeds. Notice faint bands for
streptavidin can be seen for all lanes (most prominent in 4R sample) at bottom of
gel. This is a result of unfolding the tetrameric streptavidin complex. Some
streptavidin is liberated during boiling in 1 X Laemmli buffer because only 1-2
streptavidin molecules per tetramer is covalently conjugated to the bead.
6.10 MAP2 binds to the end of Tau fibrils
One way to demonstrate that proteins are within close proximity, is to
utilize Forster resonance energy transfer (FRET) experiments. In order to
perform FRET, a donor and acceptor fluorophore are required. FRET requires
two fluorophores to have sufficient spectral overlap between the emission
spectrum of the donor and excitation spectrum of the acceptor. If sufficient
overlap exists, a non-radiative energy transfer can occur in which the energy of
an excited electron in the donor fluorophore (high energy) is transferred to and
excites an electron in the acceptor fluorophore (lower energy). Additionally,
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because this phenomenon is non-radiative, it only occurs when fluorophores are
in close proximity to one another (here 60 Å for Alexa488/Alexa 594). This
phenomenon can be measured by exciting the donor fluorophore and monitoring
emission for the acceptor. Due to the energy transfer phenomenon, the intensity
of the donor species is reduced while the acceptor species intensity increases.
If it is the case that MAP2 is binding specifically and tightly to the end of
the fibril, it is expected that this phenomenon could be observed by FRET. In
these experiments K18 Alexa 488 (donor) monomer was incorporated onto the
fibril end. The samples were excited at 450 nm and emission was measured from
500 – 675 nm. To these reactions, Alexa 594 (acceptor) labeled proteins (K18,
3R MAP2, and 4R MAP2) were added to the previous reactions. The resultant
emission spectra were measured again. It was shown that upon addition of K18,
3R MAP2, or 4R MAP2, that donor intensity decreased (peak at 520 in Figure
6.12 A - C) and acceptor intensity increased (peak at 611 nm in Figure 6.2 A –
C). Three independent batches of seeds were used, ensuring consistency and
rigor. The emission spectra were normalized for the intensity at 520 (donor
peak), averaged, and plotted with SEM (Fig 6.12 A-C). When K18 Alexa 594 was
added as an acceptor species, FRET was observed with the characteristic drop
in donor intensity (at 520 nm, black arrow) and increase in acceptor intensity (at
611 nm, red arrow). The reduction of the donor peak (520 nm) relative to the
increase in acceptor peak (611 nm) is evidence that energy transfer is occurring
between the labels and demonstrates the labels are in close proximity. Since we
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know that K18 grows efficiently on the end of the fibril, it can be extrapolated that
the MAP2 protein is also interacting with the end of the fibril due to the increase
in acceptor emission observed. If MAP2 were binding randomly along the long
axis of the fibril, it would be expected that the FRET signal would be weaker than
that of K18. Since intensities for the acceptor peak are similar, it is likely that
MAP2 is also binding to the end of the fibril.

Figure 6.12 FRET of Alexa labeled monomers. 1 µM labeled K18 was mixed with
10 µM K18 seeds and incubated 1 hour at 37 °C. Emission spectra were taken
and 1 µM of the indicated acceptors were added (K18, 3R MAP2, or 4R MAP2).
A FRET experiment of Alexa 488 and Alexa 594 labeled K18 grown on K18
results in energy transfer due to close proximity of labeled monomers on the end
of the fibril. B and C FRET signals for Alexa labeled MAP2 3R and 4R
respectively. Energy transfer occurs to a similar degree with MAP2 proteins,
indicating that they are likely binding to the end of the fibril in a similar manner to
that of K18.
To ensure this FRET signal was not a result of excess heparin in solution
(from the seeds, and a similar argument as in the anisotropy experiments)
resulting in monomer aggregation, the monomers were incubated together with
2.5 µM heparin. This amount is equal to the amount of heparin that the seeds
added would have contributed. If all of the heparin was unbound and free in
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solution. It was shown that by addition of 2.5 µM heparin, no increase in FRET
signal was observed for K18 (Fig 6.13 A). Likewise, 3R and 4R MAP2 were not
observed to have an increase in FRET signal when only heparin was added (Fig
6.13 B and C). This result is important because it suggests strongly the binding
observed is specific to the fibril and not an artifact of labeling or unbound heparin.

Figure 6.13 No FRET signal is observed when only heparin is added. 1 µM
labeled K18 was mixed with [heparin] carried over from seeds in previous
experiment (Fig 6.12) and incubated 1 hour at 37 °C. Emission spectra were
taken and 1 µM of the indicated acceptors were added (K18, 3R MAP2, or 4R
MAP2). Without the addition of seed, no FRET is observed for any of the 3
reactions (A K18, B 3R MAP2, or C 4R MAP2) despite equimolar heparin
concentrations as in seeded experiment above.
If these monomers are indeed interacting with the end of the fibril, it
should be possible to again use the biotinylated monomers in a different type of
experiment than before. Commercially available products that contain
streptavidin conjugated to gold nanoparticle exist. It is also possible to observe
these gold nanoparticles under transmission electron microscopy. This type of
experiment would allow for direct observation of the MAP2 at the end of the Tau
fibril, by way of observing a black dot of a known size (here 6 nm Au) at the
location in which the monomer has bound. It was necessary to use the constructs
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generated for the bead-capture experiments, namely the proteins with a single
cysteine residue at the N-terminus. This would ensure the PEG11-biotin
conjugation would be pointing towards the solution, where it would be able to
interact with the streptavidin conjugated nanogold. Tau fibrils were allowed to
incubate with biotinylated 3R and 4R MAP2 and then were mixed with
equivolume of diluted streptavidin conjugated gold nanoparticles (Aurion). It was
observed that a 1:20 dilution of nanoparticles with assembly buffer produced the
best results. After incubation with the gold nanoparticles for 1 hour, samples
were prepared for TEM analysis. It was shown that MAP2 proteins were binding
to the end of Tau fibrils (Fig 6.14 A - B). Since these MAP2 monomers were
conjugated with biotin, and this biotin was accessible to the streptavidin on the
gold nanoparticles, it was observed that a single or few nanoparticles were found
on the end of the Tau fibrils. This result demonstrates visually that MAP2 3R and
4R isoforms are binding to the end of the Tau fibril.
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Figure 6.14 Streptavidin gold binds to end of fibrils incubated with biotinylated
MAP2 monomers. A 3R and B 4R MAP2 conjugated to biotin binds to the end of
K18 fibrils, indicated by the presence of the gold nanoparticle at the fibril’s end.
Streptavidin binding to biotinylated monomers causes the nanoparticle to show
up only where MAP2 is present.
Now with direct evidence for MAP2 binding to the end of Tau fibrils, it
became clear how the mechanism of action for blockage is likely occurring. In the
absence of MAP2, Tau proteins elongate into long fibrils unhindered. If MAP2
monomers are included in the reaction, it is possible for the MAP2 monomers to
bind to the end of the Tau fibrils, but not allow for the next Tau monomer to bind.
Taken together, the results of anisotropic KD determination, magnetic bead
experiment, FRET, and gold nanoparticle data demonstrate in a logically
consistent fashion that the MAP2 protein binds to the end of Tau fibrils in a
specific and tight manner. Additionally, these results demonstrate that the
number of MAP2 layers that form on the end of the fibril is as few as a single
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layer. It also seems likely that the MAP2 protein, which is not interacting with the
end of the fibril, but that is sedimented in the earlier experiments, is likely due to
amorphous aggregates forming with excess heparin. The heparin titration
experiments show that the blockage effect is not caused by reduced heparin
concentration, however. It is still unknown whether or not the MAP2 protein is
interacting in an identical fashion as Tau, but it is suggested by the FRET
experiments that the MAP2 is probably binding parallel and in-register or the
FRET labels would likely be too far apart to have similar signal intensities to Tau
labeled with Alexa 594.
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Chapter 7 Discussion
7.1 Full length monomeric Tau resides in multiple conformational states
Measurements of the structure of Tau in solution demonstrated various
intramolecular interactions. Particularly, FRET experiments on monomeric Tau
resulted in distance distributions shorter than would be expected for a true
random coil [19], [129]. One study utilized introduction of Tryptophan residues
and cysteines (labeled with a fluorophore, IAEDANS) to measure FRET
efficiencies and calculate the distances between the pair of fluorophores. This
study demonstrates that the monomer alone in solution can adopt a global
hairpin-type structure [20]. Another study utilized FRET to demonstrate that
upon addition of heparin, the MTBR of Tau compacts, and the N and C termini
are forced outwards[129]. This could demonstrate the initial step towards
oligomerization of positively-charged monomers on the polyanionic heparin
scaffold. Due to limitations with the instrumentation used, molecules must be
observed in bulk solution or only briefly at the single molecule level (on the order
of milliseconds [168]).
One way to avoid these pitfalls is to utilize an instrument called the antiBrownian electrokinetic trap (ABEL trap) [123], [169]. This instrument is capable
of tracking the molecular trajectory and utilizing electromotive force to direct
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analytes of interest. Keeping analytes in the measurement cell enables
prolonged (on the order of seconds) measurements of individual proteins [123] ̶
[124], [165]. Prolonging measurement time provides better signal-to-noise and
allows for new conformational information to be elucidated.
ABEL trap instruments have been utilized to study other proteins
previously [123], [125] but the first use of this type of instrument on an
intrinsically disordered protein has been shown here and confirmed that
fundamental solution-phase behavior of monomeric Tau can be examined [127].
This proof of concept will enable development of more advanced studies that
could incorporate cofactors and/or seeds to investigate the mechanism of
monomer to fibril conversion.
It was shown in collaboration with the Goldsmith group at University
Wisconsin, Madison, that full length human Tau (the longest isoform) is present
in a bimodal distribution of fluorescence anisotropies. However, when either a
folded globular protein (microbial transglutaminase or MTG), denatured MTG, or
free dye were measured, the samples only consist of a distribution of anisotropy
best fit by one Gaussian function. This implies that these latter cases only have
one global structure. Upon denaturation, Tau no longer exhibited this bimodal
distribution. This is indicative of structural perturbation by the denaturant. To
ensure this was due to disruption of intramolecular interactions in the monomeric
state of Tau, several additional experiments were performed. First, hydrolyzed
dye and unlabeled Tau (mutated to have no cysteines) were mixed, and bulk
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anisotropy measurements were taken. Then the same experiment was
performed using the ABEL trap. The results suggest it is likely the dye is not
interacting with the protein in a non-specific manner ([127] See page 12 in the
supplement). Additionally, when a less hydrophobic dye was used (Atto 633), the
anisotropic distributions were very similar ([127] supplement, Fig S5). This also
substantiates the claim that the dye is not interacting with the protein and causing
artifactual anisotropic distributions. Utilizing molecular dynamics simulations,
dyes conjugated to proteins have been shown to track the proximal residues
[171]. If these results were purely a consequence of unfolded proteins in solution,
then the denatured MTG would likely exhibit a bimodal anisotropic distribution,
which it does not. This feature must be attributed to Tau itself, and not a
consequence of being an unfolded protein. These findings are in agreement with
other studies which show Tau has transient intramolecular interactions which
result in a structure that is more compact than expected for a random-coil [20].
Transient structure in other IDPs has been shown. For example,
Huntingtin protein is an amyloidogenic protein containing polyglutamine
expansions in the primary sequence and is considered to have intrinsically
disordered regions [167] ̶ [168] and a collapsed solution-phase structure has also
been demonstrated for polyglutamine chains [174]. Aβ fragments are also highly
flexible in solution. NMR of soluble Aβ has shown that conformational sampling
occurs and structural disorder is prevalent [175]. These transient structures are
important because they preclude true amyloid formation but might be associated
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with oligomeric states and early polymerization. It is thought that hydrophobic
regions can become exposed during this conformational sampling. These
hydrophobic patches may serve as aggregation hotspots.
This work is being followed up with additional measurements on hT40
mutants labeled with Atto 647N. Also, time-resolved anisotropy measurements of
the hT40 310 labeled with Atto 647N have been recorded. The future work
utilizing this instrument could be useful in developing a better understanding of
how initial aggregation occurs, and what factors may drive the oligomerization of
Tau.
7.2 Amyloid fibril selection and evolution
The ability to form distinct fibril conformers from proteins with identical
sequence, and to perpetuate these conformers by template-assisted conversion,
is a unique property of amyloids [69], [131]–[133], [176], [177]. Structural
polymorphism requires that the recruited proteins exhibit a high degree of
plasticity as they are molded into different conformational states, Tau proteins
possess such plasticity. It has been shown that K18 fibrils, when subjected to 5
cycles of seeding and growth, formed a heterogeneous mixture of conformers
[63]. Upon further examination, it was demonstrated that the K18 fibrils formed
from stirred material were relatively homogenous [64]. After consecutive cycles of
seeding and growth, the once dominant polymorph had become a subpopulation. To understand the context of this phenomena, it is helpful to consider
that structural evolution has been observed for other amyloids.
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Strain switching and conformational polymorphism are well documented
phenomena within the context of amyloids [144], [158], [178]. It was shown that
for prion protein, fibrils formed under different agitation conditions were
structurally unique [179]. These fibrils were shown to have differing properties
with respect to cross-β-core structure and morphology. Importantly, these unique
structural features arose when independent reactions from identical batches of
protein were agitated differently. Polymorphism was a result of monomers
adopting unique structures upon differing agitation modes, and not from
preformed nuclei within the stock monomer samples. Here we present sample
homogeneity formed during agitation and then subsequent selection of minor
subpopulations due to differences in their growth rate, which resulted in
heterogeneity in the later cycle samples.
Another example of structural polymorphism leading to strain switching
induced by differences in agitation has been shown for Aβ [70]. This study
demonstrated that if amyloidogenic proteins were incubated either quiescently or
agitated, that unique structures would arise. Aβ fibrils formed under agitation
were also shown to interconvert to the quiescently formed fibril structure, if these
fibrils were mixed together. The structural conversion took place over the course
of 35 days [70]. This process was demonstrated to be due to in part to
dissociation of monomers from the less thermodynamically stable fibril. This
allowed for elongation and growth of the more stable Aβ polymorph. It was also
demonstrated, in this work, that a change in agitation allowed for a new
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dominant structure of Tau fibril to evolve [64]. Since each reaction was sonicated
and added to new monomers, the fastest growing Tau fibril would become
dominant over time, rather than the more stable structure. Tau fibrils did not
appreciably dissociate to allow a similar mechanism of action, as measured for
Aβ, however. This could be due to cofactor interactions, causing increased
thermodynamic stability.
Surface catalyzed secondary-nucleation mechanisms have also been
suggested to cause strain switching within a single fibril [150] ̶ [151], [187].
Secondary nucleation is a phenomenon in which a new amyloid nucleus forms
on the surface of the fibril, along the long axis. This mechanism would seem to
imply branching of fibrils, though this has not been observed. It has been
suggested that these small fibrils detach from the surface easily and begin
elongation independent of the nucleation site. If fibrils are capped, fragmentationbased pathways may allow for Tau to break, and then elongate despite having
been previously capped. Fibrils have been observed to break into pieces as
small as trimers and still be seeding competent [95]. However, short fibrils
(>10mer) appear to be most seeding competent [96].
It was demonstrated that Tau fibrils are found in the brains of people with
chronic traumatic injury [11], [180], [181]. This disease is thought to be caused by
repeated concussion or head trauma [8], [9], [182]. This highlights the need to
further investigate the breakage properties of amyloids. Fragile fibrils may
spread more rapidly, as small fibrils have been shown to be selectively
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endocytosed [93], [96]. Further work needs to be done in order to better
understand how mechanisms of breakage can contribute to structural
polymorphism of amyloids found in disease. Selection processes can
interconvert the dominant Tau fibril species in solution. Changes in structure
were monitored by various techniques including: TEM, proteolytic sensitivity, and
light scattering. A study on α-synuclein showed that structural evolution, with
respect to these same biophysical properties, also occurred [183]. Additionally, it
was shown that there were different degrees of toxicity from different α-synuclein
fibril species when applied to SH-SY5Y cell culture. Using cell culture and mouse
models, Tau inclusions formed exogenously can result in unique, faithfullypropagating, strains of Tau fibrils. These phenotypes could be induced in
aggregate free cells by addition of fibril-containing cellular lysate [177], [184].
Differences in disease phenotypes may be linked to fibril conformation or
the ability of the fibril to faithfully propagate during cell-to-cell transmission.
Therefore, it is important to examine the conformational heterogeneity of amyloid
fibrils to more fully understand the processes which lead to different disease
phenotypes.
7.3 Tau fibril stability
Amyloid fibrils made of Tau are very stably folded [185]. Proteins in the
amyloid fold typically form zipper-like structures [186]–[188], which results in high
stability. Bovine spongiform encephalopathy (BSE) prion amyloids are capable of
surviving the meat rendering process, and even incineration of medical and
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agriculture byproducts[189]. Inactivation of prions and amyloids can be achieved
under harsh conditions of strong alkalinity and high temperatures [190]. This
stability could contribute to why the Tau fibrils were not dissociated upon limited
dilution. The dissociation of fibril and cofactor interactions may take place under
more extreme dilution conditions than examined here (>40x). The limit of
detection for these proteins on Coomassie stained SDS PAGE meant it was not
possible to examine greater dilutions. Silver staining or immunostaining could be
used to achieve greater sensitivity, but with greater background. ABEL traps can
overcome this limitation due to higher signal-to-noise. An ABEL trap may be used
in the future to examine fibril dissociation leading to greater understanding of
molecular behavior of Tau fibrils.
Neither K18 nor K19 fibrils were observed to release associated cofactors
under high salt conditions (500 mM). Similarly, the fibrils themselves did not
dissociate appreciably under high salt conditions. It is likely that some of the
cofactor may be very tightly associated with Tau along the long fibril axis. The
cofactor has been proposed to stabilize the parallel and in-register arrangement
of the many positive charges found in Tau [177] ̶ [178]. The fact that cofactors
can be partially exchanged [57] demonstrated that at least some of the cofactors
associated to the fibril are non-permanent. However, since neither increased salt
concentration nor dilution released bound cofactors appreciably, it is likely a
compensatory structure must replace bound cofactors [57]. The cofactor
exchange process could be responsible for cell internalization processes [161].
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Fibrils initially formed with heparin were shown to bind to sulfonated
polysaccharides on the surface of cells in culture, and this process mediated
micropinocytosis of the fibrils [161]. Additionally, it has been shown that
polyanionic molecules (cofactors) are associated with NFTs [179] ̶ [180]. This
suggests that cofactor mediated stabilization likely occurs in-vivo. The exact role
for polyanionic cofactors in disease is unclear, however, hyperphosphorylated
Tau found in disease has been shown to aggregate without a cofactor [195].
Although high-resolution structural data has become available for the AD fibril
[71], it is not clear whether fibrils formed in-vitro have the same structure. The
cryo-EM structure of Tau fibrils showed electron density in the interior of the fibril
but was not of high enough resolution to precisely understand what this electron
density is due to [71]. It is possible that this density is due to the presence of a
polyanionic cofactor. Heterogeneity within the structure of the cofactor would
obscure the molecular resolution for these structures. Further work needs to be
done to characterize the extent of cofactor mediated stabilization in disease
fibrils, and the position(s) of these cofactors within the fibril structure.
7.4 MAP2 aggregation
It has been demonstrated in the literature that NFTs are comprised
primarily of phosphorylated Tau. Antibodies raised against epitopes of MAP2 not
present in Tau, generally have little reactivity against these NFTs [196]. Claims of
epitopes from MAP2 in NFTs have been made, but cross-reactivity of antibodies
with Tau could not be fully eliminated [195] ̶ [196]. Evidence for MAP2 amyloid
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formation in the literature is scarce, but has been demonstrated in two
contradictory studies [197] ̶ [198]. The first study utilized a truncated MAP2 C
construct to generate PHF-like structures. A relatively high concentration of
recombinant 3R MAP2 MTBRs was incubated in a sitting drop crystallization
setup and allowed to aggregate for 1 - 4 weeks. The PHF-like structures formed
bound the amyloid specific dyes, ThT and ThS, and were examined using TEM.
The second study demonstrated the ability for MAP2 C to form SF-like structures
under similar concentrations and sitting-drop crystallography conditions. The
ability for MAP2 C to form PHF in this study was predicated on mutating a region
of MAP2 C to the sequence of Tau. By changing this sequence in MAP2 C to the
sequence found in Tau (4 amino acid substitutions), the ability of MAP2 C to form
SF was diminished greatly, while the ability to form PHFs was enhanced. Another
study demonstrated that if two amino acids are changed from the sequence of
MAP2 to Tau, and vice versa, the aggregation of these proteins can be
modulated [200]. In the case of the mutant Tau, amyloid formation was
decreased and an increased likelihood of granule or amorphous aggregation was
observed. The results of the experiments involving the mutated MAP2 show that
the propensity of MAP2 to form amyloid aggregates was increased when it
contained the sequence derived from Tau. These results are interesting because
the sequence that was mutated is known to be one of two very important sixresidue stretches within the larger sequence that comprises Tau amyloid
aggregates. These small regions within the MTBR region of Tau are known as
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the hexapeptide repeats. In fact, fibrils from only these hexapeptide regions have
been observed. These studies highlight that it may be possible for MAP2 to form
amyloid structures under particular conditions.
There have been almost no studies on MAP2 D aggregation. The full
length and MTBRs of MAP2 D expressed here, aggregated during the initial
purification procedure used. This required the use of 2 M urea to solubilize the
protein (see methods). It was demonstrated that the aggregation behavior of
MAP2 in the presence of heparin cofactor results in large amorphous
aggregates, which do not resemble amyloid fibrils.
7.5 Inhibition of Tau
It was shown here that MAP2 binds to the end of K18 fibrils with a lower
KD (1.6 µM for MAP2 4R and 2.8 µM for MAP2 3R vs 3.9 µM for K18 on itself)
than Tau for itself. If MAP2 is going to be a useful inhibitor of Tau aggregation, it
must interact with the fibril directly and specifically. When K19 was used as a
control, no binding was observed. This is consistent with the asymmetric seeding
barrier that has been previously described [57], [63], [130]. There are very few
other studies that demonstrate that MAP2 may inhibit Tau aggregation. One such
study has been published on a possible inhibitory role of MAP2 C on Tau
nucleation. MAP2 C was shown to inhibit Tau nucleation when a negativelycharged lipid cofactor (arachidonic acid) was used [201]. It was not fully explored
whether or not MAP2 was interacting with the arachidonic acid. Arachidonic acid
can be used in place of other polyanionic cofactors in Tau research [202]. The
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inhibition of Tau protein in this study was negated by phosphorylation of MAP2 C.
Phosphorylation of MAP2 C could result in lowered affinity for the anionic
micelles, used to induce Tau aggregation. With less MAP2 C binding to the
micelles, perhaps the Tau was again able to nucleate and form amyloid fibrils.
This study did not investigate 4R MAP2.
There are other cases of experiments in which Tau aggregation is blocked
by some type of inhibitor. Many of these examples are of small molecules [121],
[203]–[205], but there are cases of a peptide being used [206]. Seidler et al
demonstrated that mutated fragments of the Tau MTBRs made from D-amino
acids can block the aggregation of K18. This study shows that by using a known
disease related mutation, ΔK280, a steric zipper is formed between the β-sheets
and this can block the Tau aggregation [207]. This mechanism of action is
different than our proposed mechanism, because it is taking place on the side of
the protofilament. Experiments in our lab demonstrate that this mutant (K18
ΔK280) can also be blocked by MAP2 (data not shown) which is promising
because an eventual drug to treat Tau aggregation should target a variety of
sequences.
Other studies demonstrating a blocking effect on Tau aggregation typically
involve small molecule inhibitors. Some of these small molecules have been
derived from methylene blue (MB). MB and other phenothiazines have been
shown to inhibit Tau aggregation in-vitro [208]. These molecules have had limited
success at stopping disease progression in zebrafish, however [209]. These
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molecules are thought to oxidize the cysteines in Tau, as is the case for vitamin
B12 [205]. The cysteines in Tau have been shown to be important in aggregation
[210]–[212]. A small molecule that has been studied more exhaustively than most
others is (−)-epigallocatechin gallate [120], [211] ̶ [212]. One paper suggests its
ability to block aggregation occurs by either stabilizing a conformation of
monomer that is incapable of forming nuclei or by changing the monomer to an
inert state [121]. This could be important for preventing the initial aggregation
from occurring. This mechanism would not affect aggregation in a seeded
environment, such as when fibrils are transmitted from neuron to neuron [100] ̶
[101], [213].
Chaperone proteins have been shown to regulate protein refolding in the
cellular environment. Heat shock proteins (HSPs) are a class of chaperones.
HSP expression is usually regulated tightly and can be increased in response to
cellular stress, such as protein aggregation. HSP70 is a highly conserved
chaperone protein. It has been shown to bind and inhibit Tau fibril elongation also
[216]. The cellular machinery that may be responsible for disassembling Tau
fibrils in neurons has yet to be discovered. Studies do show that different
combinations of HSPs may be necessary to achieve noticeable clearance of
amyloids [217]–[219]. It is possible that the proper combination of chaperones
that would allow disaggregation of amyloids, does exist. Once a fibril has grown
to a sufficient length, natural fibril fragmentation pathways must cause breakage
and subsequent seeding for pathology to spread. Mechanisms of breakage could
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include trauma or some undiscovered combination of chaperones. If we could
harness an interaction between natural or synthetic blocking agents and Tau
fibrils, natural mechanisms such as proteolytic degradation or chaperones
mediated disassembly may clear the aggregates.
One final area of AD aggregation inhibitors to discuss is that of antibodybased drugs. These drugs have proven to be effective in mice [220]. Many of
these Aβ antibodies capture the monomer in an incompatible format, thereby
prohibiting aggregation. As an example, Bapineuzumab was shown to be safe in
Phase 2 trials [221] but produced no statistical difference in disease progression
of mild-to-moderate AD when compared to a placebo in 3 double-blind studies
[219] ̶ [220]. So far, other antibodies have had similar results [224]–[226]. These
studies demonstrate that it is possible to engineer monomer-capturing antibodies
which have encouraging results in-vitro. As for Tau, there are antibody-based
approaches demonstrating the ability to inhibit cell-to-cell transmission of Tau
fibrils in the preclinical stages that show promising results thus far [224] ̶ [225].
Further studies to demonstrate the exact region or regions of MAP2 that result in
the blockage of Tau, shown here, will need to be performed. Eventually, it may
be possible to engineer a peptide that resembles the sequence of MAP2, which
provides the same structural interference and results in reduced aggregation in
patients. The potent and rapid blocking effect demonstrated by the work here
could help shape how inhibitors are designed in the future.
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7.6 MAP2 binds to and caps the end of Tau fibrils
The end of the fibril is the location in which new monomers are added [54].
The structural information stored in the amyloid fold (such as sheet-sheet
packing and protofilament contact residues) defines the structure of fibrils during
the conversion of soluble Tau into fibrillar aggregates. This information is stored
in the “strain” or conformation. Conformational templating allows for the faithful
replication of the structure as parallel and in-register aggregates [54].
The structure of Tau fibrils can be perturbed by changing a single amino
acid residue [58]. This is because the core of the fibril is tightly packed and
changing the R-group of a single amino acid can generate unfavorable
interactions that restrict an incoming monomer from binding to and elongating the
fibril. This change in structure could the due to selection processes rather than
strain switching in one fibril. It is conceivable that if some minimum number of
MAP2 monomers bind to the end of a Tau fibril, they might provide enough
perturbation in structure that the Tau protein can no longer grow on this fibril.
This interaction may be driven by the sequence similarities between the MAP2
and Tau. However, changes to the structure then cause Tau monomer
incompatibilities because of the sequence dissimilarity to MAP2. There are 27
amino acid changes between the two sequences of truncated 4R MAP2 and K18.
These differences are likely to be responsible for the inability of MAP2 to be
recruited to an appreciable amount and elongate the Tau fibrils. This is also likely
the reason K19 was incapable of blocking K18 seeded aggregation.
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Although it is not possible to seed 3R Tau monomer on 4R fibrils [63],
[130], it is possible to form mixed fibrils where both 3R and 4R Tau are part of the
same fibril [56]. It seems that the fact that the second repeat is missing from 3R
MAP2 is inconsequential with respect to its ability to block. That region of the
protein may not need to be included in the fibril core for templating to occur.
Fibrils from AD have recently been shown to be composed of the third and fourth
repeats [71]. This may explain why 3R MAP2 may be able to successfully block
the aggregation of 4R Tau, like the 4R MAP2 isoform.
It was shown that MAP2 binds to the end of K18 fibrils and blocks Tau
aggregation. The differences in the MAP2 and Tau sequences are likely
responsible for the incapability of Tau monomers to grow on MAP2 capped fibrils
but the sequence similarity between the proteins may be the reason for this
binding. Although MAP2 does not grow on the Tau fibril as Tau would, it seems
to be possible for a single MAP2 molecule to bind to the end. Perturbations in
structure caused by differences in the two protein sequences could disfavor
additional monomers from binding. If the conformation of the fibril is perturbed
enough, it could also be that Tau is no longer capable of adopting the structure
and continuing to elongate the fibril. There is literature to support that
conformation of fibrils may not be perfectly imparted on the new monomer, and
conformational strain may switch within a single fibril [144], [158]. A similar
mechanism that results in capping, rather than true strain switching and
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elongation, could help explain why MAP2 seems to block Tau aggregation with a
single layer.
Tau fibril seeds and MAP2 monomers were initially preincubated together
for some time before the capped fibril seeds were added to fresh monomer and
heparin. These experiments resulted in potent blockage of Tau (data not shown)
and established the potential for MAP2 as a blocking agent. These types of
experiments were adjusted to the more physiologically-relevant experimental
design discussed below. By adding the fibril seeds to a mixture of MAP2
monomer, Tau monomer, and heparin, a competition between MAP2 and Tau
was forced. Small Tau fibrils have been shown to be progressively transported
down neuronal networks [215] and selectively endocytosed [93]. These small
Tau fibrils are thought to be much like the seeds used in recombinant
experiments. As previously stated, fibrils as small as trimers have been
observed, are internalized, and can induce aggregation in cells. The
simultaneous introduction of fibril material to monomers (of MAP2 and Tau) and
cofactor yielded a more biologically relevant competition-style experiment where
MAP2 and Tau proteins would have to compete for the same sites on the fibril
end. If after endocytosis of Tau fibrils, MAP2 is present – it might be possible for
the internalized fibril ends to become capped – and therefore inhibit the growth.
Mechanisms that slow the progression of Tau deposition in disease are of great
interest. This is because there are no long-term treatment options for people
afflicted with AD and other diseases. Additional work on mechanisms by which
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Tau fibril spread can be mitigated is needed. It will be critical in the future to
verify that MAP2 is able to block Tau seeding in the cell. Experiments towards
this goal are currently ongoing.
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Appendices
Appendix A Alignments

MAP2 C (3R) alignments. Shown here is the full length 3R MAP2 sequence from
humans and constructs used in this work. Highlighted in red are the repeat
regions. Red residues are cysteines, the blue star is the native cysteine used for
Atto647N labeling for anisotropy and brown star is the N-Terminal cysteine
labeled with Alexa 594 or PEG11-Biotin maleimide. Uniprot # P11137
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MAP2 D (4R) alignments. Shown here is the full length 4R MAP2 sequence from
humans and constructs used in this work. Highlighted in red are the repeat
regions. Red residues are cysteines, the blue stars are the native cysteines.
Position 440 was used for Atto647N labeling for anisotropy and the brown star is
the N-Terminal cysteine labeled with Alexa 594 or PEG11-Biotin maleimide.
Uniprot # P11137
131

4R Tau alignments. Shown here is the full length 4R Tau sequence from
humans. Shown here is the full length 3R MAP2 sequence from humans and
constructs used in this work. Highlighted in red are the repeat regions. Red
residues are cysteines, the blue stars are the native cysteines. Position 322 was
used for Atto647N labeling (anisotropy experiments) and brown star is the NTerminal cysteine labeled with Alexa 594 or PEG11-Biotin maleimide. Uniprot #
P11137
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Appendix B Magnetic bead pulldown aparatus

Streptavidin coated magnetic bead pulldown setup. A Before applying the
magnetic field, beads were homogeneously mixed in solution. B Upon placement
of the tube in a strong magnetic field, the beads would be pulled to one magnetic
pole, creating a tightly packed pellet.
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Appendix C Figures to accompany purification of Tau and MAP2

Figure Appendix C 1 Representative cation-exchange chromatograms for K18
and MAP2. Shown here are representative cation-exchange chromatograms for
K18 with the y-axis scale of A UV (mAU) and B Conductivity (mS/cm). C and D
show a representative chromatogram for MAP2 with y-axis scales for UV (mAU)
and conductivity (mS/cm), respectively. Chromatograms for K19 and 3R MAP2
are nearly indistinguishable from the 4R examples shown here.
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Figure Appendix C 2 Representative ion exchange eluent fractions of K18 and
truncated 4R MAP2 analyzed by SDS PAGE. Representative eluent fractions
from MonoS GL10/100 (GE) column for truncated A Tau (#11 - #17) and B 4R
MAP2 (#14 - #20). MAP2 elutes at a higher conductivity.
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Figure Appendix C 3 Representative UV trace for truncated Tau and MAP2 on
S75 and S200 columns, respectively. Representative UV (mAU) trace for A
Chromatogram of K18 purified over a Superdex S75 (GE) and B truncated MAP2
(4R here) purified over a Superdex S200 (GE). Black arrow represents K18 (top)
and 4R MAP2 (bottom). Chromatograms for K19 and 3R MAP2 are nearly
indistinguishable from the 4R examples shown here.
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